

## MENT COOPERATION TREA

From the INTERNATIONAL BUREAU

PCT

## **NOTIFICATION OF ELECTION**

(PCT Rule 61.2)

<b>Date of mailing</b> (day/month/year) 09 November 2000 (09.11.00)	<b>ETATS-UNIS D'AMERIQUE</b> in its capacity as elected Office
<b>International application No.</b> PCT/GB00/01247	<b>Applicant's or agent's file reference</b> GWS/MM/21034
<b>International filing date</b> (day/month/year) 31 March 2000 (31.03.00)	<b>Priority date</b> (day/month/year) 31 March 1999 (31.03.99)
<b>Applicant</b>	
FOSTER, Keith, Alan et al	

1. The designated Office is hereby notified of its election made:

in the demand filed with the International Preliminary Examining Authority on:

19 September 2000 (19.09.00)

in a notice effecting later election filed with the International Bureau on:

- ? The election  was

was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

<p><b>The International Bureau of WIPO</b>  <b>34, chemin des Colombettes</b>  <b>1211 Geneva 20, Switzerland</b></p> <p>Facsimile No.: (41-22) 740.14.35</p>	<p>Authorized officer</p> <p><b>Zakaria EL KHODARY</b></p> <p>Telephone No.: (41-22) 338.83.38</p>
---	--

**PCT**W INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>7</sup> : <b>A61K 38/16, 47/48, C07K 19/00, C12N 15/29, A61K 48/00, A61P 25/00</b>		A1	(11) International Publication Number: <b>WO 00/57897</b> (43) International Publication Date: 5 October 2000 (05.10.00)
(21) International Application Number: <b>PCT/GB00/01247</b>		(81) Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 31 March 2000 (31.03.00)  (30) Priority Data: 9907429.6 31 March 1999 (31.03.99) GB <i>31/32; 1/21/00</i>			
(71) Applicant (for all designated States except US): MICROBIOLOGICAL RESEARCH AUTHORITY [GB/GB]; CAMR, Porton Down, Salisbury, Wiltshire SP4 0JG (GB).		Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(72) Inventors; and (75) Inventors/Applicants (for US only): <del>FOSTER, Keith, Alan</del> [GB/GB]; Microbiological Research Authority CAMR, Porton Down, Salisbury, Wiltshire SP4 0JG (GB). CHADDOCK, John, Andrew [GB/GB]; Microbiological Research Authority CAMR, Porton Down, Salisbury, Wiltshire SP4 0JG (GB). QUINN, Conrad, Padraig [GB/GB]; Microbiological Research Authority CAMR, Porton Down, Salisbury, Wiltshire SP4 0JG (GB).			
(74) Agents: SCHLICH, George, William et al.; Mathys & Squire, 100 Gray's Inn Road, London WC1X 8AL (GB).			

(54) Title: USE OF A LECTIN OR CONJUGATES FOR MODULATION OF C-FIBRE ACTIVITY

## (57) Abstract

The present invention relates to the treatment of pain and to compounds that modulate C-fibre activity. In particular, the present invention relates to the use of a lectin in the manufacture of a medicament for modulation of C-fibre neurone activity, and to lectin conjugates. The lectin conjugates comprise a lectin coupled to a peptide or protein, wherein the peptide or protein is substantially free of Clostridial neurotoxin enzyme activity. The present invention also concerns methods for manufacturing said conjugates. The compounds and compositions described have particular application in the treatment of diseases of which C-fibre activity is a component. Such diseases include pain, inflammation, psoriasis and other C-fibre related conditions.

14  
PATENT COOPERATION TREATY

PCT

REC'D 24 JUL 2001

WIPO PCT

## INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference  GWS/MRM/21034	<b>FOR FURTHER ACTION</b>		See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)
International application No.  PCT/GB00/01247	International filing date (day/month/year)  31/03/2000	Priority date (day/month/year)  31/03/1999	
International Patent Classification (IPC) or national classification and IPC A61K38/16			
Applicant  MICROBIOLOGICAL RESEARCH AUTHORITY et al.			
<p>1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.</p> <p>2. This REPORT consists of a total of 7 sheets, including this cover sheet.</p> <p><input checked="" type="checkbox"/> This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).</p> <p>These annexes consist of a total of 5 sheets.</p> <p>3. This report contains indications relating to the following items:</p> <p>I    <input checked="" type="checkbox"/> Basis of the report II   <input type="checkbox"/> Priority III   <input checked="" type="checkbox"/> Non-establishment of opinion with regard to novelty, inventive step and industrial applicability IV   <input type="checkbox"/> Lack of unity of invention V   <input checked="" type="checkbox"/> Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement VI   <input type="checkbox"/> Certain documents cited VII   <input type="checkbox"/> Certain defects in the international application VIII   <input checked="" type="checkbox"/> Certain observations on the international application</p>			

Date of submission of the demand  19/09/2000	Date of completion of this report  20.07.2001
Name and mailing address of the international preliminary examining authority:  European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465	Authorized officer  Didelon, F  Telephone No. +49 89 2399 7332



# INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/GB00/01247

## I. Basis of the report

1. With regard to the **elements** of the international application (*Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17)*):  
**Description, pages:**

1-3,5-39	as originally filed		
4,4a	as received on	23/04/2001 with letter of	20/04/2001

### Claims, No.:

1-29	with telefax of	09/07/2001
------	-----------------	------------

### Drawings, sheets:

1/13-13/13	as originally filed
------------	---------------------

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language: , which is:

- the language of a translation furnished for the purposes of the international search (under Rule 23.1(b)).
- the language of publication of the international application (under Rule 48.3(b)).
- the language of a translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- contained in the international application in written form.
- filed together with the international application in computer readable form.
- furnished subsequently to this Authority in written form.
- furnished subsequently to this Authority in computer readable form.
- The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. The amendments have resulted in the cancellation of:

# INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/GB00/01247

- the description,        pages:
- the claims,              Nos.:
- the drawings,        sheets:

5.  This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):  
*(Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.)*
6. Additional observations, if necessary:

### **III. Non-establishment of opinion with regard to novelty, inventive step and industrial applicability**

1. The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non-obvious), or to be industrially applicable have not been examined in respect of:
  - the entire international application.
  - claims Nos. 20-23 (with respect to industrial applicability).because:
  - the said international application, or the said claims Nos. 20-23 relate to the following subject matter which does not require an international preliminary examination (*specify*):  
**see separate sheet**
  - the description, claims or drawings (*indicate particular elements below*) or said claims Nos. are so unclear that no meaningful opinion could be formed (*specify*):
  - the claims, or said claims Nos. are so inadequately supported by the description that no meaningful opinion could be formed.
  - no international search report has been established ~~for~~ the said claims Nos. .
2. A meaningful international preliminary examination cannot be carried out due to the failure of the nucleotide and/or amino acid sequence listing to comply with the standard provided for in Annex C of the Administrative Instructions:
  - the written form has not been furnished or does not comply with the standard.
  - the computer readable form has not been furnished or does not comply with the standard.

### **V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT**

International application No. PCT/GB00/01247

1. Statement

Novelty (N)	Yes:	Claims	1-6, 8-29
	No:	Claims	
Inventive step (IS)	Yes:	Claims	16, 8-29
	No:	Claims	
Industrial applicability (IA)	Yes:	Claims	1-19, 24-29
	No:	Claims	

2. Citations and explanations

**see separate sheet**

**VIII. Certain observations on the international application**

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

**see separate sheet**

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/GB00/01247

**Comments on item III:**

Claims 21-23 relate to methods of treatment of the human/animal body, which is subject-matter considered by this Authority to be covered by the provisions of Rule 67.1(iv) PCT. Consequently, no opinion will be formulated with respect to the industrial applicability of the subject-matter of these claims (Article 34(4)(a)(i) PCT).

**Comments on item V:**

1. The amendments filed with telefax of 09.07.2001 were found to be admissible and do not introduce new subject-matter.
  
2. Reference is made to the following documents :

D1: WO 96 33273 A; THE SPEYWOOD LABORATORY LTD &  
MICROBIOLOGICAL RESEARCH AUTHORITY (1996-10-24)

D3: US-A- 5,433,946 (ALLEN, H.J. ET AL.), HEALTH RESEARCH INC. (1995-07-18)

3. Document D1 discloses that botulinum toxin derivatives, especially LH<sub>N</sub> fragments, act as inhibitors of sensory afferents, like C-fibres and are used in the control of pain (see claims 1-40 and 51 in particular). This document also reveals that such toxin derivatives are to be associated to Targeting Moieties (TM) in order to direct them to their site of action on the nerves. Among those TMs, the use of lectins is disclosed.

The present application shows that lectins, on their own, have a negative effect on nerve conduction effect, in particular they have a clear and sustained analgesic effect (see in particular Examples 5, 7, 14, 16, 18, 19). D1 discloses lectins conjugated with the active LH<sub>N</sub> botulinic toxin in the treatment of pain, but since the lectin is only used to target the toxin, i.e., the active principle, to the nociceptive neurons, the subject-matter of claims 1-4, 17-23 (partially) appears to be novel and to involve an inventive activity.

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/GB00/01247

4. The present application also considers conjugates (and their nucleic acid) or combinations formed by a lectin and a peptide or protein free of Clostridial neurotoxin enzyme activity, and their uses in the treatment of the various diseases of the invention (claims 5-29).

Document D3 reveals a lectin-protein conjugate, wherein the lectin is a **human** galactoside-binding lectin, namely galaptin (see column 4, lines 61-62), and wherein the protein is a lysosomal enzyme, for the treatment of lysosomal storage diseases.

The disclaimer introduced in claim 6 seems to be allowable and makes the above mentioned claims novel since it specifically excludes the disclosure of D3, wherein a different technical problem is to be solved.

It appears however that the disclaimer of claim 7 is not allowable since a disclaimer must be precisely defined and limited to the accidental novelty-destroying disclosure.

It cannot be allowed for the only purpose of "further clarifying" the distinction with the prior art, as if a distinction exists than the prior art is not novelty-destroying. New subject-matter would be indirectly introduced when a disclaimer is broader than strictly necessary since the boundaries of what has been disclaimed also constitutes the common limits of what is claimed.

The example 11 describes evidence of an analgesic effect of a Clostridial toxin free of clostridial activity in combination with one of the lectins of the invention. Example 17 shows the preparation of a mutant form of LH<sub>N</sub>/A deprived of Clostridial toxin activity.

As a consequence, the lectin-protein conjugates as well as the non-conjugated lectin-protein of the invention are considered as solving the technical problem of treating the recited diseases.

Novelty and inventive activity can therefore be acknowledged for claims 5, 6, 8-29.

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/GB00/01247

5. For the assessment of the present claims 20-23 on the question whether they are industrially applicable, no unified criteria exist in the PCT Contracting States. The patentability can also be dependent upon the formulation of the claims. The EPO, for example, does not recognize as industrially applicable the subject-matter of claims to the use of a compound in medical treatment, but may allow, however, claims to a known compound for first use in medical treatment and the use of such a compound for the manufacture of a medicament for a new medical treatment.

**Comments on item VIII:**

1. The expressions reciting the treatment of condition resulting from modulation, inhibition, stimulation of C-fibre activity, found in claims 1, 4, 5, 16-18, 20-22 and 28 do not define specific diseases but instead appears to define the diseases to be treated in terms of the mechanism of action, in other words as a result to be achieved. Since it is possible to define the diseases more narrowly as in claims 19, 23 or 29, the above identified functional definition results in a lack of clarity of said claims and contravenes Article 6 PCT.
2. Examples 3, 4, **6**, 9, 10, 11 and 16 (as well as their corresponding figures) are not considered do not fall within the scope of the claims. These examples are all contemplating conjugates having a LH<sub>N</sub>A active toxin, in other words retaining the Clostridial enzyme activity, contrary to claims 5, 6, 8-29.  
This inconsistency between the claims and the description leads to doubt concerning the matter for which protection is sought, especially with regard to D1, thereby rendering the claims unclear (Article 6 PCT).
3. Claims 28-29 appear to be unclearly defined (Article 6 PCT) since they recite "the use of a pharmaceutical composition for the manufacture of a medicament for treating...". A redundancy appears between pharmaceutical composition and medicament, which are considered as synonyms. It is to be noted that the first part of such claims usually define the active product *per se*.

- 4 -

of pain. Each element, receptor, chemical mediator, neurotransmitter, ion channel and synapse, in this complex pathway is a potential target for blockade.

5      The current analgesic standards are the opiates, for example morphine. While these compounds are effective in a range of pain conditions, they do not provide a panacea. Their effects are short lived, thus requiring frequent application. Furthermore, there are associated unpleasant side effects of respiratory depression, nausea, dependency, addiction and induction of  
10     tolerance.

Activity of C-fibres is also implicated in the modulation of mucus release in disease conditions such as those involving mucus hypersecretion.

15     It is an object of the present invention to provide new methods and compositions for treatment of pain and for treatment of C-fibre related disease conditions such as inflammation, psoriasis, mucus hypersecretion and pain.

20     Accordingly, a first aspect of the invention provides the use of a lectin in manufacture of a medicament for modulation of C-fibre neurone activity. The first aspect of the invention also provides a method of modulating C-fibre activity by administering an effective amount of lectin.

25     In use of an embodiment of the invention, a lectin administered in a pharmaceutical composition binds to a C-fibre neurone and inhibits transmission of nerve cell impulses via that neurone, treating and thereby reducing a disease condition caused by or involving excessive activity of that C-fibre neurone.

30     Oligosaccharide carbohydrate receptors regulate key stages in many physiological processes of pharmaceutical importance such as inflammation, oncology, immunology, neural, infectious and other types of diseases

- 40 -

CLAIMS

- RECEIVED  
APR 30 2000  
AMERICAN  
PATENT OFFICE
1. Use of a lectin in the manufacture of a medicament for modulation of C-fibre neurone activity.
  - 5 2. Use according to Claim 1 of a lectin specific for galactosyl residues.
  3. Use according to Claim 1 of a lectin specific for glucosyl residues.
  - 10 4. Use of a nucleic acid sequence encoding the lectin defined in any of Claims 1-3 in the manufacture of medicament for modulation of C-fibre neurone activity.
  - 15 5. A pharmaceutical composition comprising a first lectin, and a pharmaceutically acceptable carrier and/or diluent, wherein the composition is substantially free of Clostridial neurotoxin enzyme activity.
  6. A composition according to Claim 5 wherein the first lectin is specific for galactosyl residues.
  - 20 7. A composition according to Claim 5 wherein the first lectin is specific for glucosyl residues.
  - 25 8. A composition according to any of Claims 5-7 comprising a peptide or protein; or a pharmaceutical composition comprising a first lectin, a peptide or protein substantially free of Clostridial neurotoxin enzyme activity, and a pharmaceutically acceptable carrier and/or diluent.
  9. A composition according to Claim 8 wherein the peptide or protein is a second lectin and the first and second lectins are different.
  - 30 10. A composition according to Claim 9 wherein the first lectin is specific

- 41 -

for galactosyl residues and the second lectin is specific for glycosyl residues.

11. A composition according to Claim 8 wherein the peptide or protein is an endopeptidase or a Clostridial neurotoxin substantially free of enzyme activity.

12. A composition according to any of Claims 5-11, wherein the first lectin and/or the second lectin if present is a lectin derivative, said derivative having been modified to remove a carbohydrate group whilst maintaining the ability of the derivative to bind C-fibres.

13. A composition comprising one or more nucleic acid sequence encoding the lectin/s recited in Claims 5-10, or one or more nucleic acid sequence encoding the lectin and peptide/protein recited in Claim 11.

15

14. A conjugate comprising a first lectin coupled to a peptide or protein, wherein said peptide or protein is substantially free of Clostridial neurotoxin enzyme activity and optionally has a C-fibre modulation activity.

20

15. A conjugate according to Claim 14 wherein the peptide or protein is a second lectin.

16. A conjugate according to Claim 14 or 15 wherein the first lectin is specific for galactosyl residues.

25

17. A conjugate according to Claim 14 or 15 wherein the first lectin is specific for glucosyl residues.

30

18. A conjugate according to Claim 15 wherein the first and second lectins are different.

19. A conjugate according to Claim 18 wherein the first lectin is specific for

- 42 -

galactosyl residues and the second lectin is specific for glucosyl residues.

20. A conjugate according to Claim 14, wherein the peptide or protein is an endopeptidase, or a Clostridial neurotoxin substantially free of enzyme 5 activity.
- 10 21. A conjugate according to any of Claims 14-20 wherein the first lectin and/or the second lectin if present is a lectin derivative, said derivative having been modified to remove a carbohydrate group whilst maintaining the ability of the derivative to bind C-fibres.
- 15 22. A nucleic acid sequence encoding the conjugate of any of Claims 14-20.
- 20 23. Use of a composition according to any of Claims 5-13, or use of a conjugate according to any of Claims 14-21, or use of a nucleic acid sequence according to Claim 22, in the manufacture of a medicament for modulation of C-fibre activity.
- 25 24. Use according to any of Claims 1-4 or 23 for treatment of a disease or condition selected from pain, psoriasis, inflammation and mucus hypersecretion.
- 25 25. Use of a composition according to any of Claims 1-4 or 23 for inhibition of C-fibre activity.
- 30 26. Use of a composition according to any of Claims 1-4 or 23 for stimulation of C-fibre activity.
- 30 27. A method of modulating C-fibre activity comprising administering an effective amount of a lectin, or a composition according to any of Claims 5-13, or a conjugate according to any of Claims 14-21, or a nucleic acid

- 43 -

sequence according to Claim 22, to a patient.

28. A method according to Claim 27 for inhibiting C-fibre activity.

5 29. A method according to Claim 27 for stimulating C-fibre activity.

30. A method according to any of Claims 27-29 for treating a disease or condition selected from pain, psoriasis, inflammation and mucus hypersecretion.

10

31. A method of preparing a conjugate according to any of Claims 14-21, comprising coupling together, optionally via a linker, the first lectin and the peptide or protein.

15

32. A method of preparing a conjugate according to any of Claims 14-21, comprising expressing in a host a nucleic acid sequence according to Claim 22, optionally including a linker nucleic acid sequence located within the nucleic acid sequence of Claim 22 to provide a linker molecule between the first lectin and the peptide or protein of the conjugate.


20

# PATENT COOPERATION TREATY

From the  
INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

To:

MACLEAN, Martin R.  
MATHYS & SQUIRE  
100 Gray's Inn Road  
London WC1X 8AL  
GRANDE BRETAGNE



PCT

## NOTIFICATION OF TRANSMITTAL OF THE INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Rule 71.1)

Date of mailing  
(day/month/year) 20.07.2001

Applicant's or agent's file reference  
GWS/MRM/21034

### IMPORTANT NOTIFICATION

International application No.  
PCT/GB00/01247

International filing date (day/month/year)  
31/03/2000

Priority date (day/month/year)  
31/03/1999

Applicant

MICROBIOLOGICAL RESEARCH AUTHORITY et al.

1. The applicant is hereby notified that this International Preliminary Examining Authority transmits herewith the international preliminary examination report and its annexes, if any, established on the international application.
2. A copy of the report and its annexes, if any, is being transmitted to the International Bureau for communication to all the elected Offices.
3. Where required by any of the elected Offices, the International Bureau will prepare an English translation of the report (but not of any annexes) and will transmit such translation to those Offices.

#### 4. REMINDER

The applicant must enter the national phase before each elected Office by performing certain acts (filing translations and paying national fees) within 30 months from the priority date (or later in some Offices) (Article 39(1)) (see also the reminder sent by the International Bureau with Form PCT/IB/301).

Where a translation of the international application must be furnished to an elected Office, that translation must contain a translation of any annexes to the international preliminary examination report. It is the applicant's responsibility to prepare and furnish such translation directly to each elected Office concerned.

For further details on the applicable time limits and requirements of the elected Offices, see Volume II of the PCT Applicant's Guide.

Name and mailing address of the IPEA/

European Patent Office  
D-80298 Munich  
Tel. +49 89 2399 - 0 Tx: 523656 epmu d  
Fax: +49 89 2399 - 4465

Authorized officer

Exner, K  
Tel.+49 89 2399-7826



PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference GWS/MRM/21034	<b>FOR FURTHER ACTION</b>		See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)
International application No. PCT/GB00/01247	International filing date (day/month/year) 31/03/2000	Priority date (day/month/year) 31/03/1999	
International Patent Classification (IPC) or national classification and IPC A61K38/16			
Applicant MICROBIOLOGICAL RESEARCH AUTHORITY et al.			
<p>1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.</p> <p>2. This REPORT consists of a total of 7 sheets, including this cover sheet.</p> <p><input checked="" type="checkbox"/> This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).</p> <p>These annexes consist of a total of 5 sheets.</p>			
<p>3. This report contains indications relating to the following items:</p> <ul style="list-style-type: none"> <li>I    <input checked="" type="checkbox"/> Basis of the report</li> <li>II    <input type="checkbox"/> Priority</li> <li>III    <input checked="" type="checkbox"/> Non-establishment of opinion with regard to novelty, inventive step and industrial applicability</li> <li>IV    <input type="checkbox"/> Lack of unity of invention</li> <li>V    <input checked="" type="checkbox"/> Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement</li> <li>VI    <input type="checkbox"/> Certain documents cited</li> <li>VII    <input type="checkbox"/> Certain defects in the international application</li> <li>VIII    <input checked="" type="checkbox"/> Certain observations on the international application</li> </ul>			

Date of submission of the demand 19/09/2000	Date of completion of this report 20.07.2001
Name and mailing address of the international preliminary examining authority:  European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465	Authorized officer  Didelon, F  Telephone No. +49 89 2399 7332



# INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/GB00/01247

## I. Basis of the report

1. With regard to the **elements** of the international application (*Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17)*):  
**Description, pages:**

1-3,5-39	as originally filed		
4,4a	as received on	23/04/2001 with letter of	20/04/2001

### Claims, No.:

1-29	with telefax of	09/07/2001
------	-----------------	------------

### Drawings, sheets:

1/13-13/13	as originally filed
------------	---------------------

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language: , which is:

- the language of a translation furnished for the purposes of the international search (under Rule 23.1(b)).
- the language of publication of the international application (under Rule 48.3(b)).
- the language of a translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- contained in the international application in written form.
- filed together with the international application in computer readable form.
- furnished subsequently to this Authority in written form.
- furnished subsequently to this Authority in computer readable form.
- The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. The amendments have resulted in the cancellation of:

# INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/GB00/01247

- the description,      pages:
- the claims,      Nos.:
- the drawings,      sheets:

5.  This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):  
*(Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.)*

6. Additional observations, if necessary:

### III. Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

1. The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non-obvious), or to be industrially applicable have not been examined in respect of:
- the entire international application.
  - claims Nos. 20-23 (with respect to industrial applicability).

because:

- the said international application, or the said claims Nos. 20-23 relate to the following subject matter which does not require an international preliminary examination (*specify*):  
**see separate sheet**
  - the description, claims or drawings (*indicate particular elements below*) or said claims Nos. are so unclear that no meaningful opinion could be formed (*specify*):
  - the claims, or said claims Nos. are so inadequately supported by the description that no meaningful opinion could be formed.
  - no international search report has been established for the said claims Nos. .
2. A meaningful international preliminary examination cannot be carried out due to the failure of the nucleotide and/or amino acid sequence listing to comply with the standard provided for in Annex C of the Administrative Instructions:
- the written form has not been furnished or does not comply with the standard.
  - the computer readable form has not been furnished or does not comply with the standard.

### V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT**

International application No. PCT/GB00/01247

**1. Statement**

Novelty (N)	Yes:	Claims 1-6, 8-29
	No:	Claims
Inventive step (IS)	Yes:	Claims 16, 8-29
	No:	Claims
Industrial applicability (IA)	Yes:	Claims 1-19, 24-29
	No:	Claims

**2. Citations and explanations  
see separate sheet**

**VIII. Certain observations on the international application**

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:  
**see separate sheet**

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/GB00/01247

**Comments on item III:**

Claims 21-23 relate to methods of treatment of the human/animal body, which is subject-matter considered by this Authority to be covered by the provisions of Rule 67.1(iv) PCT. Consequently, no opinion will be formulated with respect to the industrial applicability of the subject-matter of these claims (Article 34(4)(a)(i) PCT).

**Comments on item V:**

1. The amendments filed with telefax of 09.07.2001 were found to be admissible and do not introduce new subject-matter.
2. Reference is made to the following documents :
  - D1: WO 96 33273 A; THE SPEYWOOD LABORATORY LTD & MICROBIOLOGICAL RESEARCH AUTHORITY (1996-10-24)
  - D3: US-A- 5,433,946 (ALLEN, H.J. ET AL.), HEALTH RESEARCH INC. (1995-07-18)
3. Document D1 discloses that botulinum toxin derivatives, especially LH<sub>N</sub> fragments, act as inhibitors of sensory afferents, like C-fibres and are used in the control of pain (see claims 1-40 and 51 in particular). This documents also reveals that such toxin derivatives are to be associated to Targeting Moieties (TM) in order to direct them to their site of action on the nerves. Among those TMs, the use of lectins is disclosed.

The present application shows that lectins, on their own, have a negative effect on nerve conduction effect, in particular they have a clear and sustained analgesic effect (see in particular Examples 5, 7, 14, 16, 18, 19). D1 discloses lectins conjugated with the active LH<sub>N</sub> botulinic toxin in the treatment of pain, but since the lectin is only used to target the toxin, i.e., the active principle, to the nociceptive neurons, the subject-matter of claims 1-4, 17-23 (partially) appears to be novel and to involve an inventive activity.

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/GB00/01247

4. The present application also considers conjugates (and their nucleic acid) or combinations formed by a lectin and a peptide or protein free of Clostridial neurotoxin enzyme activity, and their uses in the treatment of the various diseases of the invention (claims 5-29).

Document D3 reveals a lectin-protein conjugate, wherein the lectin is a **human** galactoside-binding lectin, namely galaptin (see column 4, lines 61-62), and wherein the protein is a lysosomal enzyme, for the treatment of lysosomal storage diseases.

The disclaimer introduced in claim 6 seems to be allowable and makes the above mentioned claims novel since it specifically excludes the disclosure of D3, wherein a different technical problem is to be solved.

It appears however that the disclaimer of claim 7 is not allowable since a disclaimer must be precisely defined and limited to the accidental novelty-destroying disclosure. It cannot be allowed for the only purpose of "further clarifying" the distinction with the prior art, as if a distinction exists than the prior art is not novelty-destroying. New subject-matter would be indirectly introduced when a disclaimer is broader than strictly necessary since the boundaries of what has been disclaimed also constitutes the common limits of what is claimed.

The example 11 describes evidence of an analgesic effect of a Clostridial toxin free of clostridial activity in combination with one of the lectins of the invention. Example 17 shows the preparation of a mutant form of LH<sub>N</sub>/A deprived of Clostridial toxin activity.

As a consequence, the lectin-protein conjugates as well as the non-conjugated lectin-protein of the invention are considered as solving the technical problem of treating the recited diseases.

Novelty and inventive activity can therefore be acknowledged for claims 5, 6, 8-29.

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT - SEPARATE SHEET**

---

International application No. PCT/GB00/01247

5. For the assessment of the present claims 20-23 on the question whether they are industrially applicable, no unified criteria exist in the PCT Contracting States. The patentability can also be dependent upon the formulation of the claims. The EPO, for example, does not recognize as industrially applicable the subject-matter of claims to the use of a compound in medical treatment, but may allow, however, claims to a known compound for first use in medical treatment and the use of such a compound for the manufacture of a medicament for a new medical treatment.

**Comments on item VIII:**

1. The expressions reciting the treatment of condition resulting from modulation, inhibition, stimulation of C-fibre activity, found in claims 1, 4, 5, 16-18, 20-22 and 28 do not define specific diseases but instead appears to define the diseases to be treated in terms of the mechanism of action, in other words as a result to be achieved. Since it is possible to define the diseases more narrowly as in claims 19, 23 or 29, the above identified functional definition results in a lack of clarity of said claims and contravenes Article 6 PCT.
2. Examples 3, 4, **6**, 9, 10, 11 and 16 (as well as their corresponding figures) are not considered do not fall within the scope of the claims. These examples are all contemplating conjugates having a LH<sub>N</sub>/A active toxin, in other words retaining the Clostridial enzyme activity, contrary to claims 5, 6, 8-29. This inconsistency between the claims and the description leads to doubt concerning the matter for which protection is sought, especially with regard to D1, thereby rendering the claims unclear (Article 6 PCT).
3. Claims 28-29 appear to be unclearly defined (Article 6 PCT) since they recite "the use of a pharmaceutical composition for the manufacture of a medicament for treating...". A redundancy appears between pharmaceutical composition and medicament, which are considered as synonyms. It is to be noted that the first part of such claims usually define the active product *per se*.

[REDACTED]

- 4 -

of pain. Each element, receptor, chemical mediator, neurotransmitter, ion channel and synapse, in this complex pathway is a potential target for blockade.

5 WO96/33273 describes toxin conjugates comprising a clostridial neurotoxin component and a Targeting Moiety selected to target peripheral sensory afferents. The clostridial neurotoxin component of the conjugate possess a protease activity specific for components of the neurosecretory machinery (see Claim 1). Amongst a large number of potential Targeting Moieties (see  
10 pages 24 and 25), lectins are listed (see line 12 on page 13).

EP-A-602686 describes the use of lectin concentrates obtained from mistletoe in raising the natural immune resistance in humans and mammals, and/or for tumour therapy. In more detail, the lectin concentrates contain a high  
15 proportion of immunologically active galactose-specific lectin designated ML1.

The current analgesic standards are the opiates, for example morphine. While these compounds are effective in a range of pain conditions, they do not provide a panacea. Their effects are short lived, thus requiring frequent  
20 application. Furthermore, there are associated unpleasant side effects of respiratory depression, nausea, dependency, addiction and induction of tolerance.

Activity of C-fibres is also implicated in the modulation of mucus release in  
25 disease conditions such as those involving mucus hypersecretion.

It is an object of the present invention to provide new methods and compositions for treatment of pain and for treatment of C-fibre related disease conditions such as inflammation, psoriasis, mucus hypersecretion and pain.  
30

Accordingly, a first aspect of the invention provides the use of a lectin in manufacture of a medicament for modulation of C-fibre neurone activity. The first aspect of the invention also provides a method of modulating C-fibre activity by administering an effective amount of lectin.

35 In use of an embodiment of the invention, a lectin administered in a pharmaceutical composition binds to a C-fibre neurone and inhibits

4a

transmission of nerve cell impulses via that neurone, treating and thereby  
reducing a disease condition caused by or involving excessive activity of that  
5 C-fibre neurone.

Oligosaccharide carbohydrate receptors regulate key stages in many  
physiological processes of pharmaceutical importance such as inflammation,  
oncology, immunology, neural, infectious and other types of diseases

- 40 -

CLAIMS

- 5        1. Use of a lectin in the manufacture of a medicament for treating a disease or condition resulting from an inhibition or stimulation of C-fibre neuron activity, by modulation of C-fibre neuron activity.
- 10      2. Use according to Claim 1 of a lectin which binds to a galactosyl residue.
- 15      3. Use according to Claim 1 of a lectin which binds to a glucosyl residue.
- 20      4. Use of a nucleic acid sequence encoding the lectin defined in any of Claims 1-3 in the manufacture of medicament for treating a disease or condition resulting from an inhibition or stimulation of C-fibre neuron activity, by modulation of C-fibre neuron activity.
- 25      5. Use of a conjugate comprising a first lectin coupled to a peptide or protein wherein said peptide or protein is free of Clostridial neurotoxin enzyme activity, or use of a nucleic acid sequence encoding said conjugate, in the manufacture of a medicament for treating a disease or condition resulting from an inhibition or stimulation of C-fibre neuron activity; by modulation of C-fibre neuron activity.
- 30      6. A conjugate comprising a first lectin coupled to a peptide or protein, wherein said first lectin is non-endogenous to humans, and wherein said peptide or protein is free of Clostridial neurotoxin enzyme activity.
- 35      7. A conjugate according to Claim 6, wherein said first lectin is non-endogenous to vertebrates.
8.      8. A conjugate according to Claim 6 or Claim 7 wherein the peptide or protein is a second lectin.
9.      9. A conjugate according to Claim 8 wherein the first and second lectins are different.
10.     35 10. A conjugate according to any of Claims 6-9 wherein the first lectin binds to a galactosyl residue.

- 41 -

11. A conjugate according to any of Claims 6-9 wherein the first lectin binds to a glucosyl residue.
12. A conjugate according to Claim 9 wherein the first lectin binds to a galactosyl residues and the second lectin binds to a glucosyl residue.  
5
13. A conjugate according to Claim 6 or Claim 7, wherein the peptide or protein is an endopeptidase, or a Clostridial neurotoxin free of enzyme activity.
- 10 14. A conjugate according to any of Claims 6-13 wherein the first lectin and/or the second lectin if present is a lectin derivative, said derivative having been modified to remove a carbohydrate group whilst maintaining the ability of the derivative to bind C-fibres.
- 15 15. A nucleic acid sequence encoding the conjugate of any of Claims 6-13.
16. Use of a conjugate according to any of Claims 6-14, or use of a nucleic acid sequence according to Claim 15, in the manufacture of a medicament for treating a disease or condition resulting from an inhibition or stimulation of C-fibre neuron activity, by modulation of C-fibre activity.  
20
17. Use according to any of Claims 1-5 or 16 for inhibition of C-fibre activity.
18. Use according to any of Claims 1-5 or 16 for stimulation of C-fibre activity.  
25
19. Use according to any of Claims 1-5 or 16-18 for treatment of a disease or condition selected from pain, psoriasis, inflammation, mucus hypersecretion, rhinitis, erythema, irritable bowel syndrome, headache, asthma, and arthritis.
- 30 20. A method of treating a disease or condition resulting from an inhibition or stimulation of C-fibre neuron activity, by modulating C-fibre activity, comprising administering an effective amount of a lectin, or a conjugate according to any of Claims 6-14, or a nucleic acid sequence according to Claim 15, to a patient.
- 35 21. A method according to Claim 20 for inhibiting C-fibre activity.
22. A method according to Claim 20 for stimulating C-fibre activity.

- 42 -

23. A method according to any of Claims 20-22 for treating a disease or condition selected from pain, psoriasis, inflammation, mucus hypersecretion, rhinitis, erythema, irritable bowel syndrome, headache, asthma, and arthritis.
- 5 24. A method of preparing a conjugate according to any of Claims 6-14, comprising coupling together, optionally via a linker, the first lectin and the peptide or protein.
- 10 25. A method of preparing a conjugate according to any of Claims 6-14, comprising expressing in a host cell a nucleic acid sequence according to Claim 15, optionally including a linker nucleic acid sequence located within the nucleic acid sequence of Claim 15 to provide a linker molecule between the first lectin and the peptide or protein of the conjugate.
- 15 26. A pharmaceutical composition comprising a lectin and a peptide or protein, wherein the peptide or protein is an endopeptidase or a Clostridial neurotoxin free of enzyme activity.
- 20 27. A pharmaceutical composition according to Claim 26, wherein the peptide or protein is an LH<sub>N</sub> fragment of a Clostridial neurotoxin.
- 25 28. Use of a pharmaceutical composition according to Claim 26 or Claim 27, in the manufacture of a medicament for treating a disease or condition resulting from an inhibition or stimulation of C-fibre neuron activity, by modulation of C-fibre activity.
29. Use according to Claim 28 for treatment of a disease or condition selected from pain, psoriasis, inflammation, mucus hypersecretion, rhinitis, erythema, irritable bowel syndrome, headache, asthma, and arthritis.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

## USE OF A LECTIN OR CONJUGATES FOR MODULATION OF C-FIBRE ACTIVITY

The present invention relates to the treatment of pain and to compounds that modulate C-fibre activity, in particular the use of these compounds for the treatment of diseases of which C-fibre activity is a component, such as pain, inflammation, psoriasis and other C-fibre related conditions, to methods and compositions therefor and manufacture of those compositions.

A number of disease conditions are known to be related to or associated with activity in C-fibre neurones, in particular pain, inflammation and psoriasis.

C-fibres are small diameter, unmyelinated neurones, which have their sensory termini and cell bodies in the peripheral nervous system (PNS), but which synapse in the dorsal horn of the spinal cord within the central nervous system (CNS). The accepted role of these afferent fibres is to signal strong, injury-threatening (noxious) stimuli or the presence of chemical irritants, including many inflammatory mediators to the CNS. The neurones are thus termed nociceptors. However, the importance of C-fibre neurons in a variety of other clinical conditions is only now emerging.

Uniquely amongst afferent neurones, many C-fibre nociceptors also have efferent, antidromic actions within the peripheral tissue that they innervate. When stimulated, the C-fibres release vasoactive mediators, which have potent actions on local blood vessels and on cells of the immune system. This invariably results in the phenomenon termed neurogenic inflammation. C-fibre efferent neurones store and co-release upon stimulation the neuropeptides substance P (SP) and calcitonin gene related peptide (CGRP). Both of these peptides are potently vasoactive and the blood vessel dilation by CGRP combined with an increase in SP induced vascular permeability results in plasma extravasation and peripheral oedema. This in turn recruits infiltration by eosinophils and other inflammatory cells and subsequently the full panoply of an inflammatory cascade.

- 2 -

Most citations report neurogenic inflammation in the skin. However, C-fibres are distributed widely throughout the body. In bronchial airway tissues, substances released from nociceptive terminals may cause smooth muscle contraction and also trigger the secretion of mucus. Detailed information is 5 also available for C-fibre mediated effects in the bladder and the gastrointestinal tract. Neurogenic inflammation has now been clearly associated with a variety of disorders including asthma, ulcer formation and headache. It may also be a component of generalised inflammatory responses such as arthritis.

10

Psoriasis is a hyperproliferative epidermal disease whose aetiopathogenesis remains largely undefined. However, one of the most favoured hypotheses is that the condition correlates with an altered release of SP and CGRP neuropeptides by sensory efferent neurones.

15

Studies of neurogenic inflammation in psoriatic skin have demonstrated that morphological contact between mast cells and sensory C-fibres increases in developing (1-3 weeks) psoriatic lesions when compared to non-lesional controls. This increase reaches statistical significance in mature lesions. It is 20 considered that the associated increase in neurogenic stimulation promotes mast cell degranulation and the release of inflammatory mediators. This in turn allows entry into the lesional dermis of various mediators that interact with keratinocytes to promote the hyperproliferation characteristic of psoriatic plaques.

25

A variety of psoriasis treatments are available ranging from moisturising creams, phototherapy and topical vitamin applications to corticosteroids and immune suppressants. However, none of these are universally effective nor do they appear to treat the underlying causes of the disease. Furthermore, 30 the most effective treatments, especially for conditions requiring intensive therapy, have unpleasant and often toxic side effects.

- 3 -

- Pain can be classified in a number of ways depending upon the cause, the mechanism of action and the duration of suffering. Pain can also be categorised by the level of discomfort, *e.g.* mild, moderate or severe. Most pain is caused by direct mechanical, thermal or chemical damage to specific sensory receptors (nociceptors) which are located in the skin, muscle, some viscera and a number of other tissues. The perception of "feeling pain" follows the transduction and transmission of a noxious stimulus from the site of this insult or damage to the higher centres of the Central Nervous System (CNS).
- 10 Transduction of the majority of pain signals arises from the activation of small diameter, thinly myelinated or non-myelinated neurones known as A<sub>δ</sub>- and C-fibres respectively. These fibres have their cell bodies in the dorsal root ganglia, juxtaposed along the length of the spinal column. They synapse primarily in dorsal horn laminae I and II of the spinal cord. The most common nociceptors are innervated by C-fibres.
- 15 The transmission of a pain stimulus (nociception) is a complex process. There are many chemical transmitters involved at the site of insult and throughout the Peripheral Nervous System (PNS) and CNS. For each of these chemical transmitters there is also an associated receptor, or group of receptors, which transduce and transmit the pain impulse.
- 20 Receptors can be designated as either excitatory or inhibitory. Activation of excitatory receptors causes neuronal firing, resulting in either an increase in neurotransmitter release or an increase in the excitability of neurones. In contrast, activation of inhibitory receptors causes a decrease in neuronal firing, a reduction in transmitter release and may cause a reduction in neurone excitability.
- 25

30 The interaction of pain neurotransmitters with their receptors provides a large number of potential intervention points for novel therapies for the treatment

- 4 -

of pain. Each element, receptor, chemical mediator, neurotransmitter, ion channel and synapse, in this complex pathway is a potential target for blockade.

5       The current analgesic standards are the opiates, for example morphine. While these compounds are effective in a range of pain conditions, they do not provide a panacea. Their effects are short lived, thus requiring frequent application. Furthermore, there are associated unpleasant side effects of respiratory depression, nausea, dependency, addiction and induction of  
10      tolerance.

Activity of C-fibres is also implicated in the modulation of mucus release in disease conditions such as those involving mucus hypersecretion.

15      It is an object of the present invention to provide new methods and compositions for treatment of pain and for treatment of C-fibre related disease conditions such as inflammation, psoriasis, mucus hypersecretion and pain.

20      Accordingly, a first aspect of the invention provides the use of a lectin in manufacture of a medicament for modulation of C-fibre neurone activity. The first aspect of the invention also provides a method of modulating C-fibre activity by administering an effective amount of lectin.

25      In use of an embodiment of the invention, a lectin administered in a pharmaceutical composition binds to a C-fibre neurone and inhibits transmission of nerve cell impulses via that neurone, treating and thereby reducing a disease condition caused by or involving excessive activity of that C-fibre neurone.

30      Oligosaccharide carbohydrate receptors regulate key stages in many physiological processes of pharmaceutical importance such as inflammation, oncology, immunology, neural, infectious and other types of diseases

- 5 -

(Edmonds, B. J. and Koenig, E. [1990] *Cell Motil. Cytoskeleton*, **17**, 106-17; Edmonds, B. J. and Koenig, E. [1991] *J. Neurocytol.* **20**, 232-47; Gupta, D., Arango, R. and others [1994] *Biochemistry*, **33**, 2503-08). Lectins are a class of proteins, often glycoproteins, that bind to carbohydrate structures and are known to agglutinate cells and/or precipitate complex carbohydrates. Two publications describing how lectins bind to neuronal cells are Silverman, J. D. and Kruger, L. (1990), selective neuronal glycoconjugate expression in sensory and autonomic ganglia: relation of lectin reactivity to peptide and enzyme markers, *J. Neurophysiol.* **19**, 789-801; and Streit, W.J., Schulte, B.A., Balentine, D. and Spicer, S.S. (1985), histochemical localization of galactose-containing glycoconjugates in sensory neurons and their processes in the Central and Peripheral Nervous System of the rat, *J. Histochem. Cytochem.* **33**, 1042-52. Lectins can be isolated from a wide range of natural sources including seeds, plant roots and bark, fungi, bacteria, seaweed and across the whole range of life forms from viruses to mammals. Some antibodies may mimic the *in vivo* activity of lectins. The most commonly exploited sources of lectins are the seeds of plants. The precise physiological role of lectins in nature is still unknown, but they have proved to be very valuable in a wide variety of applications *in vitro* including blood grouping and histochemical staining for cell surface markers. It is known in the literature that lectins have demonstrable selectivity for cells of different origin.

Due to the ubiquitous nature of oligosaccharide structures, lectins bind to a large number of cells. However, because of the known complexity and specificity of the transduction and transmission pathways of C-fibre neurones, it is particularly surprising and unexpected that lectins can bind to neurones so as to modulate C-fibre and/or A<sub>δ</sub>-fibre activity. For the purposes of this invention a "lectin" or a "lectin domain" is the whole of or that part of a peptide, protein or glycoprotein, or mimic thereof, that has the ability to bind specifically to mono- or oligosaccharide structures. The invention is of application without limit to particular sub-groups of lectins, though preferred lectins are those that bind galactosyl residues, for example terminal β-D-

- 6 -

galactosyl or terminal  $\alpha$ -D-galactosyl residues or N-acetylgalactosamine residues, or glucosyl residues.

In use of an embodiment of the invention, a lectin binds to a surface structure 5 or structures (the Binding Site [BS]) which is characteristic of, and has a degree of specificity for relevant sensory effector cells and/or neurones in the peripheral or central nervous system responsible for the afferent or projection transmission of pain or the regulation of said transmission. Next, it modulates the function of such cells so that either the transduction or transmission of 10 the pain signal is reduced or abolished. Such modulation may be due to suppression of the activity of afferent and or projection neurones or due to promotion of the activity of inhibitory neurones.

One aspect of the invention thus advantageously provides a further class of 15 analgesic compositions and uses of these compositions for treatment of pain. The invention provides use of a lectin in manufacture of a medicament for treatment of pain and a method of treatment of pain comprising administration of an effective amount of a lectin. In specific embodiments of the invention, lectins have been tested using the mouse hot plate model - an industry 20 standard model acknowledged as predictive of human response - and found to be analgesic. The mouse hot-plate model is acknowledged as a model for human pain in Heilman, R. D. *et al.* (1976): An evaluation of the hot plate technique to study narcotic analgesics. *Res. Comm. Chem. Pathol. Pharmacol.* 13 (4), 635-647.

25 The lectin applications of the present invention have demonstrated equivalent latency, prolonged duration and equivalent potency when compared with the analgesic effects of morphine.

30 In a specific embodiment of the invention a galactoseries-specific lectin is extracted from the coral tree *Erythrina cristagalli* and administered intrathecally, exhibiting strong analgesic activity. In a further specific

- 7 -

embodiment of the invention a galactoseries-specific lectin is extracted from the coral tree *Erythrina corallodendron* and administered intrathecally, also exhibiting strong pain-reducing activity. These illustrative lectins are heterodimeric and homodimeric glycoproteins respectively of approximate 5 molecular weight of 60kDa (Arango, R. and others [1992] *Eur. J. Biochem.* **205**, 575-81). In a still further specific embodiment of the invention, a glucosyl-specific lectin is analgesic in the mouse hot plate model.

- A list of commercially available lectins appears in the 1998 Sigma catalogue. 10 A further example of a lectin, specifically a bacterial lectin is PA-I from *Pseudomonas aeruginosa*. This is a D-galactose binding lectin with a molecular weight of 13kDa (Garber, N., Guempel, U. and others (1992). *Biochim. Biophys. Acta.* **1116**, 331-3).
- 15 In use of a further embodiment of the invention, a lectin binds to a C-fibre neurone that innervates a psoriatic lesion and inhibits release of inflammatory modulators, including substance P. A further aspect of the innovation thus advantageously provides a class of compositions for treatment of psoriasis.
- 20 In use of a still further embodiment of the invention, a lectin binds to a C-fibre neurone which modulates mucus release or control of mucus release. A still further aspect of the invention thus advantageously provides a class of composition and uses thereof for treatment of mucus hypersecretion.
- 25 Site and mode of delivery of lectin is typically a factor in obtaining the desired therapeutic effect. Thus, a topically and/or specifically delivered composition containing a lectin can comprise a lectin that binds to C-fibres but is not specific for C-fibres. By way of example, an embodiment of the invention provides for treatment of a localised disease condition such as psoriasis, using 30 a lectin formulated in a cream which can be topically applied or a lectin formulated for sub-dermal injection. In this way, delivery of a lectin according to the invention is targeted and not systemic. In the case particularly of

- 8 -

formulations for injection, it is optional to include a further pharmaceutically active substance to assist retention at or reduce removal of the lectin from the site of administration, and one example is the use of a vasoconstrictor such as adrenaline. Such a formulation confers the advantage of increasing the 5 residence time of lectin following administration and thus increasing and/or enhancing its effect.

Similar targeting delivery is appropriate for diseases involving C-fibre activity and for which the active lectin can be delivered via aerosol or other spray. An 10 aerosol formulation of a lectin enables delivery to the lungs and/or other nasal and/or bronchial or airway passages, facilitating use of lectin for treatment of diseases such as mucus hypersecretion and rhinitis (hay fever).

Generally, the invention is of application to treatment of diseases caused by 15 or exacerbated by antidromic activity in C-fibres, by inhibition of the antidromic activity, which is typically at least partially self-perpetuating or of an origin that is not clearly defined or presently understood. More specifically, the compounds and formulations of the invention can be used for treatment of inflammation including neurogenic inflammation, erythema, 20 irritable bowel syndrome, headache, asthma, arthritis and as already mentioned pain including migraine.

Lectins and lectin domains may be arranged, covalently or non-covalently, so 25 as to form oligomers and/or polymers, their functional units optionally separated using linkages which may include one or more spacer arms. The chemical conjugation and genetic fusion of such domains can be achieved by conventional methods. Lectins and lectin domains may be coupled to a distinct, additional, lectin or non-lectin companion protein forming a multi-component agent such that the efficacy of the agent is enhanced when 30 compared to the native lectin component alone. Such an agent is optionally the expression product of a recombinant gene which provides for a minimal functional peptide domain such that the agent may be monomeric in form and

- 9 -

may optionally be glycosylated. The agent may be the expression product of a recombinant gene delivered independently to the preferred site of action of the agent. Gene delivery technologies are widely reported in the literature (reviewed in "Advanced Drug Delivery Reviews" Vol. 27, [1997, Elsevier Science Ireland Ltd].

Methods for extracting and purifying lectins are known in the literature, for example, Iglesias, J. L., Lis, H. and Sharon, N. (1982) *Eur. J. Biochem.* **123**, 247-252.

Gene expression technologies for the provision of functional, recombinant lectins, both glycosylated and non-glycosylated, are known in the literature (Arango, R. and others [1992] *Eur. J. Biochem.* **205**, 575-81). By way of example, a cDNA encoding a lectin can be cloned into any of the pET series of plasmid vectors. Expression of the gene is thus under control of the T7 promoter and can be well regulated in the *E. coli* host. The expression product is recovered and purified from inclusion bodies using established techniques. These methods have been shown to produce non-glycosylated lectin proteins that otherwise retain all of the known functions of the native lectins.

Recombinant lectin protein fusions may be made by a variety of approaches. For example, the fusion of a gene coding for a lectin to a gene coding for a second lectin or non-lectin protein. These gene fusions may be separated by a further nucleic acid sequence coding for a flexible linker region (*e.g.* a polyglycine tract) which facilitates interaction of the fused proteins either with themselves (oligomerisation) or with other target molecules (receptors, other lectins etc.).

The lectin may further be expressed in single copy or multicopy arrangements on the surface of bacteriophage such that the monomers may associate to form a functional oligomeric molecule. In some instances, functionality may

- 10 -

request the association of two or more separate bacteriophage displaying or require expressing lectin monomers. This approach may also be used for the expression of lectin fusion proteins.

5       The present invention further provides a composition comprising a lectin as described coupled to another peptide or protein. The peptide or protein may be a carrier or may impart a second function to the composition in addition to the C-fibre modulatory properties of the lectin. The peptide or protein may itself have a C-fibre and/or A<sub>δ</sub>-fibre modulatory property. The modulatory 10      property of the peptide or protein may be independent from that of the lectin. Alternatively, the peptide or protein may modify the C-fibre and/or A<sub>δ</sub>-fibre modulatory property of the lectin.

15     The peptide or protein may be any molecule which is substantially free from Clostridial neurotoxin enzyme activity. Consistent with this definition, the peptide or protein may be, for example, a non-Clostridial toxin of plant or microbial origin, including but not limited to bacterial toxins. Further Examples 20      of suitable peptides or proteins include inactive LH<sub>N</sub>/A (ie. inactive Clostridial neurotoxin), a second lectin (which may be the same as the first lectin or different), or multiple lectin conjugates (eg. dimers or trimers, etc).

25     Thus, the lectin molecule of the present invention may be employed as a targeting moiety to direct the peptide or protein to relevant sensory effector cells and/or neurones in the PNS or CNS responsible for the afferent or projection transmission or pain or the regulation of said transmission. The peptide or protein may then exert a C-fibre and/or A<sub>δ</sub>-fibre modulation property at the target site.

30     The lectin of the present invention helps the *in vivo* stabilization of the peptide or protein.

In one embodiment, the present invention provides a composition comprising

- 11 -

a first lectin conjugated to a second lectin, the lectins being optionally different or the same. All conjugate embodiments of the present invention may be coupled directly or via an intermediate linker. The lectins of the invention may also be modified to make derivatives, for example modified to remove a carbohydrate group whilst maintaining its ability to bind target cells.

In another embodiment, the peptide or protein is an endopeptidase, suitably of Clostridial origin. Specifically, the lectin of the invention can be coupled to an endopeptidase from a clostridial species, optionally from botulinum neurotoxin type A, or B. Such compositions are conveniently made by coupling a galactose-binding lectin to an enzymatically active fragment of a Clostridial neurotoxin, for example an LH<sub>N</sub> fragment of a botulinum neurotoxin, and in an illustrative example set out below a galactose-binding lectin from *Erythrina cristagalli* is coupled to an LH<sub>N</sub> fragment of botulinum neurotoxin type A. The present invention thus still further provides a method of preparing a composition of the invention by covalently attaching a lectin to another peptide or protein.

The lectin of the invention either in isolated form or incorporated into compounds or compositions may exert its activity by preventing the release of a neurotransmitter or neuromodulator from a primary sensory afferent, by inhibiting the release of a neurotransmitter or neuromodulator from a primary nociceptive afferent, by inhibiting the release of a neurotransmitter or neuromodulator from a projection neurone, by promoting the activity of an inhibitory neurone or by a combination thereof.

The lectin of the invention may be optionally modified such that it possesses minimal or substantial no C-fibre and/or A $\delta$ -fibre modulation property. However, in this embodiment, the lectin either retains or possesses a targeting specificity to relevant sensory effector cells and/or neurones in the PNS or CNS which is preferably at least comparable with that of unmodified lectin. Thus, in this embodiment, the lectin simply targets the peptide or

- 12 -

protein. Such modification may be achieved, for example, by random mutagenesis or site-directed mutagenesis of lectin- or conjugate-encoding nucleic acid or by direct chemical modification of the lectin or lectin conjugate.

5

In another aspect of the present invention, the peptide or protein is not coupled to the lectin. According to this embodiment, it is however preferred that the peptide or protein is associated with the lectin by, for example, a non-covalent linkage, an electrostatic interaction and/or Van der Waal's forces.

10

To this end, the lectin and/or the peptide or protein may be modified by introducing complementary surface charges which facilitate association of the two components *in vitro* and *in vivo*. Such modification may include 15 introducing positively or negatively charged groups (eg. chemical groups or amino acid groups) into exposed surfaces on either or both of the two components.

20

Another aspect of the invention lies in a method of modulating C-fibre activity comprising administering an effective amount of a lectin to a patient. The lectin can be used to inhibit C-fibre activity, or to stimulate C-fibre activity.

25

Further aspects of the invention lie in a composition for modulation of C-fibre activity comprising a nucleic acid encoding a lectin, a method of modulating C-fibre activity comprising administering an effective amount of such a composition, and use of such a composition in manufacture of a medicament for modulation of C-fibre activity.

30

In a yet further aspect, the invention provides a pharmaceutical composition for modulation of C-fibre neurone activity, comprising  
a lectin or a composition according to any of the above aspects of the invention; and

- 13 -

at least one of a pharmaceutically acceptable carrier, excipient, adjuvant, propellant and or salt.

The compound may thus be formulated for oral, parenteral, continuous infusion, inhalation or topical application and encompasses delivery of the lectin or conjugate its nucleic acid coding sequence or its agonists. Intraspinal injection is another route of administration, though the present invention encompasses also any administration that delivers the compound to an appropriate or optimal site of intervention. Administration might take advantage of a variety of delivery technologies including microparticle encapsulation, viral delivery systems or high pressure aerosol impingement, including delivering a lectin-coding nucleic acid to a cell population in which it would be expressed and the gene product would be capable of effecting analgesia. Additionally, the target cells for lectin activity need not be the cells in which the gene is expressed.

Agents of the invention for treatment of pain may be administered to a patient by intrathecal or epidural injection in the spinal column at the level of the spinal segment involved in the innervation of an affected organ. This is, for example, applicable in the treatment of deep tissue pain, such as chronic malignant pain. The dosage ranges for administration of the compounds of the present invention are those to produce the desired therapeutic effect. It will be appreciated that the dosage range required depends on the precise nature of the lectin or composition, the route of administration, the nature of the formulation, the age of the patient, the nature, extent or severity of the patient's condition, contraindications, if any, and the judgement of the attending physician. Wide variations in the required dosage, however, are to be expected depending on the precise nature of the agent. Variations in these dosage levels can be adjusted using standard empirical routines for optimisation.

Fluid dosage forms are typically prepared utilising the compound and a

- 14 -

pyrogen-free sterile vehicle. The compound, depending on the vehicle and concentration used, can be either dissolved or suspended in the vehicle. In preparing solutions the compound can be dissolved in the vehicle, the solution being made isotonic if necessary by addition of sodium chloride and sterilised  
5 by filtration through a sterile filter using aseptic techniques before filling into suitable sterile vials or ampoules and sealing. Alternatively, if solution stability is adequate, the solution in its sealed containers may be sterilised by autoclaving. Advantageously additives such as buffering, solubilising, stabilising, preservative or bactericidal, suspending or emulsifying agents and  
10 or local anaesthetic agents may be dissolved in the vehicle.

Dry powders, which are dissolved or suspended in a suitable vehicle prior to use, may be prepared by filling pre-sterilised drug substances and other ingredients into a sterile container using aseptic technique in a sterile area.  
15 Alternatively the drug and other ingredients may be dissolved into suitable containers using aseptic technique in a sterile area. The product is then freeze dried and the containers are sealed aseptically.

Compositions suitable for administration via spinal injection may be made up  
20 in a conventional manner and employed in conjunction with conventional administration devices.

Compositions of the previously filed International patent application PCT/GB98/03001 that contain lectins may be used in the present invention  
25 but are excluded from the scope of compositions claimed herein.

There now follows description of specific embodiments of the invention,  
illustrated by drawings in which:-

30 Fig. 1 shows a denaturing polyacrylamide gel analysis of ECL lectin, LH<sub>N</sub>/A companion protein and the subsequent chemical conjugates;

- 15 -

Fig. 2 shows the analgesic effect of *Erythrina cristagalli* lectin in mice in a hot-plate model;

5 Fig. 3 shows the analgesic effect of lectin-conjugates is comparable to a supramaximal dose of morphine in mice in a hot-plate model;

Fig. 4 shows WGA lectin is analgesic in the mouse hot plate model;

10 Fig. 5 shows that *Bandeirea simplicifolia* lectin IB<sub>4</sub> is analgesic in the mouse hot plate model;

Fig. 6 illustrates SDS-PAGE analysis of a conjugate of wheat-germ agglutinin lectin and a companion protein (WGA-LH<sub>N</sub>/A);

15 Fig. 7 illustrates non-reducing SDS-PAGE analysis of a purified conjugate of *Erythrina corallodendron* lectin and a companion protein (ECorL-LH<sub>N</sub>/A);

Fig. 8 illustrates SDS-PAGE analysis of a purified conjugate of *Bandeiraea simplicifolia* and a companion protein (IB<sub>4</sub>-LH<sub>N</sub>/A);

20 Fig. 9 illustrates SDS-PAGE analysis of conjugated oligomeric *Erythrina cristagalli* lectin (ECL);

25 Fig. 10 illustrates modulation of substance P release by *Erythrina cristagalli* lectin;

Fig. 11 illustrates modulation of substance P release by *Erythrina cristagalli* lectin conjugated to another protein (LH<sub>N</sub>/A(-));

30 Fig. 12 illustrates inhibition of C-fibre response to stimulation by *Erythrina cristagalli* lectin;

- 16 -

Fig. 13 illustrates antidromic effects of the *Erythrina cristagalli* lectin.

Fig. 14 Inhibition of response to painful thermal stimuli following application of *Erythrina cristagalli* to the mouse spinal cord *in vivo*.

5

Some of the above Figures are now described in more detail below:-

In Fig. 2, lectin was applied intrathecally (30 $\mu$ g in a 5 $\mu$ l vehicle volume). Onset of lectin-induced analgesia reaches a plateau at 1 hour post application 10 and remains constant for at least 5 hours. Morphine achieves a maximal effect at 1 hour and then returns to control levels over a period of 5 hours. (Data is the mean of replicate readings from groups of 10 mice  $\pm$  SE).

In Fig. 3, lectin-conjugate was applied intrathecally (30 $\mu$ g in a 5 $\mu$ l vehicle 15 volume). Onset of lectin-conjugate induced analgesia reaches a plateau at 1 hour post application and remains constant for at least 5 hours. Lectin-conjugate analgesia is similar to a supramaximal dose (20X EC50) of morphine in this test, but is of much longer duration; morphine achieves a maximal effect at 1 hour and then returns to control levels over a period of 5 hours. 20 (Data is the mean of replicate readings from groups of 10 mice  $\pm$  SE).

In Fig. 6, protein fractions were subjected to 4-20% polyacrylamide SDS-PAGE prior to staining with Coomassie blue. Lanes 6-8 were run in the presence of 0.1M DTT. Lanes 1 (&7) and 2 (& 8) represent derivatised WGA 25 and derivatised LH<sub>N</sub>/A respectively. Lanes 3-5 represent conjugation mixture, post-Superose-12 chromatography and post GlcNAc-affinity chromatography respectively. Lanes 6 represents a sample of reduced final material. Approximate molecular masses (kDa) are indicated on the Figure.

30 In Fig. 7: Lane 1 = molecular weight markers; Lane 2 = post-affinity purified sample; and Lane 3 = pre-affinity purified sample.

- 17 -

In Fig. 8: Lanes 2 & 9 = molecular markers (Novex, Mark 12); Lanes 3 & 4 = IB<sub>4</sub>-LH<sub>N</sub>/A; and Lanes 6 & 7 = IB<sub>4</sub>-LH<sub>N</sub>/A reduced by addition of 0.1M DTT.

In Fig. 9:  $\alpha$  represents lectin monomers;  $\beta$  represents lectin dimers;  $X$  represents lectin oligomers; Lane 1 = Mark 12 molecular markers; Lane 2 = ECL; Lane 3 = ECL derivatised with SMPB; Lane 4 = ECL derivatised with SPDP; Lane 5 = non-reduced oligomeric ECL-ECL mix; Lane 6 = Mark 12 molecular markers; Lane 7 = Reduced SMPB-derivatised ECL; Lane 8 = Reduced SPDP-derivatised ECL; and Lane 9 = Reduced ECL-ECL conjugate mix.

In Fig. 10, data are presented as the mean of at least three determinations  $\pm$  SEM.

In Fig. 11, conjugate was applied to eDRG neurons for three days prior to determination of the release of substance P. Released substance P was related to controls to determine % release;

The invention thus provides lectins and lectin derivatives useful *inter alia* for the treatment of pain and components for synthesis of molecules as described in WO94/21300, WO96/33273, and WO99/17806.

- 18 -

**Example 1.**

**Preparation of *Erythrina cristagalli* lectin.**

5 Lectins from *E. cristagalli* may be prepared as described by Iglesias, J. L., Lis, H. and Sharon, N. (1982) *Eur. J. Biochem.* **123**, 247-252. Alternatively the purified lectin may be purchased from a range of suppliers such as Sigma.

**Example 2.**

10

**Method for the preparation of oligomers of *Erythrina cristagalli* lectin.**

*Materials*

15 *E. cristagalli* lectin (ECL) was obtained from Sigma Ltd. SPDP was from Pierce Chemical Co. PD-10 desalting columns were from Pharmacia. Dimethylsulphoxide (DMSO) was kept anhydrous by storage over a molecular sieve. Denaturing sodium dodecylsulphate polyacrylamide gel electrophoresis (SDS-PAGE) was performed using gels and reagents from Novex. Immobilised lactose-agarose was obtained from Sigma Ltd. Additional reagents were 20 obtained from Sigma Ltd.

*Method*

The lyophilised lectin was rehydrated in phosphate buffered saline (PBS; 10mM Na<sub>2</sub>HPO<sub>4</sub>, 140mM NaCl, 2.7mM KCl, 1.8mM KH<sub>2</sub>PO<sub>4</sub>, pH7.3) to a final concentration of 10 mg/ml. Aliquots of this solution were stored at -20°C until used.

25 For conjugation the lectin was reacted with an equal concentration of SPDP by the addition of a 10mM stock solution of SPDP in DMSO with mixing. 30 After one hour at room temperature the reaction was terminated by desalting into PBS over a PD-10 column.

- 19 -

From one aliquot of the SPDP derivatised lectin material the thiopyridone leaving group was removed by reduction with dithiothreitol (DTT, 5mM, 30 min). The product of this reaction was analysed spectrophotometrically at 280 nm and 343 nm to determine the degree of derivatisation achieved. The 5 degree of derivatisation achieved was  $0.8 \pm 0.06$  mol/mol. The thiopyridone and DTT were removed by once again desalting into PBS over a PD-10 column.

A second aliquot of SPDP derivatised lectin material protein was desalted into 10 PBSE (PBS containing 1mM EDTA).

The bulk of the derivatised ECL lectin and the DTT treated derivatised ECL were mixed in proportions such that the DTT treated derivatised ECL was in greater than three-fold molar excess. The oligomerisation reaction was 15 allowed to proceed for  $> 16$  h at 4°C.

The product mixture was centrifuged to clear any precipitate that had developed. The supernatant was concentrated by centrifugation through concentrators (with 10000-50000 molecular weight exclusion limit), dialysed 20 against PBS, and stored at 4°C until use.

The oligomerisation products were analysed by SDS-PAGE on 4-20% polyacrylamide gradient gels, followed by staining with Coomassie Blue.

25 **Example 3.**

**Method for the preparation of a conjugate between *Erythrina cristagalli* lectin and a companion protein.**

30 **Materials**

*E. cristagalli* lectin (ECL) was obtained from Sigma Ltd. The companion protein in this example is a clostridial enzyme designated LH<sub>N</sub>/A and was prepared

- 20 -

essentially by the method of Shone C.C., Hambleton, P., and Melling, J. 1987, *Eur. J. Biochem.* **167**, 175-180. SPDP was from Pierce Chemical Co. PD-10 desalting columns were from Pharmacia. Dimethylsulphoxide (DMSO) was kept anhydrous by storage over a molecular sieve. Denaturing sodium 5 dodecylsulphate polyacrylamide gel electrophoresis (SDS-PAGE) was performed using gels and reagents from Novex. Immobilised lactose-agarose was obtained from Sigma Ltd. Additional reagents were obtained from Sigma Ltd.

10 *Method*

The lyophilised lectin was rehydrated in phosphate buffered saline (PBS; 10mM Na<sub>2</sub>HPO<sub>4</sub>, 140mM NaCl, 2.7mM KCl, 1.8mM KH<sub>2</sub>PO<sub>4</sub>, pH7.3) to a final concentration of 10 mg/ml. Aliquots of this solution were stored at -20°C until used.

15

The lectin was reacted with an equal concentration of SPDP by the addition of a 10mM stock solution of SPDP in DMSO with mixing. After one hour at room temperature the reaction was terminated by desalting into PBS over a PD-10 column.

20

The thiopyridone leaving group was removed from the product by reduction with dithiothreitol (DTT, 5mM, 30 min). The product of this reaction was analysed spectrophotometrically at 280 nm and 343 nm to determine the degree of derivatisation achieved. The degree of derivatisation achieved was 25 0.8±0.06 mol/mol. The thiopyridone and DTT were removed by once again desalting into PBS over a PD-10 column.

30 The companion protein was desalted into PBSE (PBS containing 1mM EDTA). The resulting solution (0.5-1.0 mg/ml) was reacted with a four- or five-fold molar excess of SPDP by addition of a 10mM stock solution of SPDP in DMSO. After 3 h at room temperature the reaction was terminated by desalting over a PD-10 column into PBS.

- 21 -

A portion of the derivatised companion protein was removed from the solution and reduced with DTT (5mM, 30 min). This sample was analysed spectrophotometrically at 280 nm and 343 nm to determine the degree of derivatisation. The degree of derivatisation achieved was  $2.26 \pm 0.10$  mol/mol. The bulk of the derivatised companion protein and the derivatised ECL were mixed in proportions such that the ECL was in greater than three-fold molar excess. The conjugation reaction was allowed to proceed for >16 h at 4°C.

The product mixture was centrifuged to clear any precipitate that had developed. The supernatant was concentrated by centrifugation through concentrators (with 10000-50000 molecular weight exclusion limit) prior to a two step purification strategy. As the first step, the concentrated material was applied to a Superose 12 column on an FPLC chromatography system (Pharmacia). The column was eluted with PBS and the elution profile followed at 280 nm.

Fractions were analysed by SDS-PAGE on 4-20% polyacrylamide gradient gels, followed by staining with Coomassie Blue. The major band of conjugate has an apparent molecular mass of between 130-160kDa; this is separated from the bulk of the remaining unconjugated companion protein and more completely from the unconjugated ECL. Fractions containing conjugate were pooled prior to the second chromatography step; immobilised lactose-agarose. Selected post-Superose-12 fractions were applied to PBS-washed lactose-agarose and incubated for 2 hours at 4°C to facilitate binding. Lectin-containing protein conjugates remained bound to the agarose during subsequent washing with PBS to remove contaminants. Lectin conjugate was eluted from the column by the addition of 0.3M lactose (in PBS) and the elution profile followed at 280 nm. The fractions containing conjugate were pooled, dialysed against PBS, and stored at 4°C until use. Figure 1 shows a typical SDS-PAGE profile of ECL lectin, companion LH<sub>N</sub>/A and the conjugation products at different stages during purification.

- 22 -

**Example 4.**

**The production of a conjugate between a lectin from *Erythrina corallodendron* and a companion protein.**

5

The procedure for production of a conjugate between a lectin from *Erythrina corallodendron* and LH<sub>N</sub>/A is essentially as described in Example 3 but with the following differences:

10      *Materials*

Lectin from *E. corallodendron* (ECorL) was obtained from Sigma Ltd.

**Example 5.**

15      **In vivo analgesic effects of *Erythrina cristagalli* lectin**

*Animals*

Adult outbred mice (MF1) of either sex, weight range 20 to 30g have been used for these studies. All animals are acclimatised for a minimum of 4 days by maintaining them in the room in which the tests are to be carried out. Pre-injection data is acquired from all animals on the day before test substances are introduced and this serves as baseline data for individual animals. In addition, this pre-test data allows screening of animals exhibiting extreme responses to the various stimuli. Experiments are done on groups of 10 animals with replicate readings taken at each test point.

*Intrathecal administration.*

Mice are anaesthetized by induction with 4% fluothane carried in a 50:50 mixture of oxygen and nitrous oxide with a flow rate of 400-500cc per minute. Once anaesthesia is induced the percentage is reduced to 1.5 to 2% for maintenance.

- 23 -

The pelvis of the mouse is located, the fur is clipped around the appropriate area and a small incision (about 5mm) is made in the skin above the spinal column.

- 5     Using a 30 gauge disposable needle attached to a 50 $\mu$ l Hamilton syringe with luer fitting the lectin material is injected into the intrathecal space. The site of injection is normally chosen to be between lumbar vertebrae 5 and 6. Holding the syringe at an angle of about 20° above the vertebral column the needle is inserted into the tissue to one side of the vertebrae so that it slips 10    into the groove between the spinous and transverse processes. The needle is then moved carefully forward to the intervertebral space whilst decreasing the angle of the syringe to about 10°. Once inserted into the appropriate 15    spot a characteristic flick of the tail is often, but not invariably, observed. 5 $\mu$ l of test material is then injected into the intrathecal space and the needle withdrawn. The skin incision is then closed with a single wound clip and the animal placed in a box to allow recovery. Mice have been observed to recover rapidly from this procedure and become fully mobile within two minutes.
- 20    *E. cristagalli* lectin agents were applied intrathecally at 30 $\mu$ g in a 5 $\mu$ l volume of physiological saline vehicle. The data in Figure 2 shows a rapid onset of lectin induced analgesia which approaches a maximum within 1 hour of application and remains constant for at least 5 hours. Lectin induced analgesia 25    is similar to that of a 10 $\mu$ g/mouse supramaximal (20 times the mouse EC50) maximal effect at 1 hour and then declines over a period of 5 hours.

**Example 6.**

- 30    ***In vivo* analgesic effects of *Erythrina cristagalli* lectin conjugates.**

*Animals*

- 24 -

Adult outbred mice (MF1) of either sex, weight range 20 to 30g have been used for these studies. All animals are acclimatised for a minimum of 4 days by maintaining them in the room in which the tests are to be carried out. Pre-injection data is acquired from all animals on the day before test substances are introduced and this serves as baseline data for individual animals. In addition, this pre-test data allows screening of animals exhibiting extreme responses to the various stimuli. Experiments are done on groups of 10 animals with replicate readings taken at each test point.

10     *Intrathecal administration.*

Mice are anaesthetized by induction with 4% fluothane carried in a 50:50 mixture of oxygen and nitrous oxide with a flow rate of 400-500cc per minute. Once anaesthesia is induced the percentage is reduced to 1.5 to 2% for maintenance.

15

The pelvis of the mouse is located, the fur is clipped around the appropriate area and a small incision (about 5mm) is made in the skin above the spinal column.

20

Using a 30 gauge disposable needle attached to a 50 $\mu$ l Hamilton syringe with luer fitting the lectin material is injected into the intrathecal space. The site of injection is normally chosen to be between lumbar vertebrae 5 and 6. Holding the syringe at an angle of about 20° above the vertebral column the needle is inserted into the tissue to one side of the vertebrae so that it slips into the groove between the spinous and transverse processes. The needle is then moved carefully forward to the intervertebral space whilst decreasing the angle of the syringe to about 10°. Once inserted into the appropriate spot a characteristic flick of the tail is often, but not invariably, observed. 5 $\mu$ l of test material is then injected into the intrathecal space and the needle withdrawn. The skin incision is then closed with a single wound clip and the animal placed in a box to allow recovery. Mice have been observed to recover rapidly from this procedure and become fully mobile within two

- 25 -

minutes.

5        *E. cristagalli* lectin-LH<sub>N</sub>/A conjugates were applied intrathecally at 30 $\mu$ g in a 5 $\mu$ l volume of physiological saline vehicle. The data in Figure 3 shows a rapid onset of lectin-conjugate induced analgesia which approaches a maximum within 1 hour of application and remains constant for at least 5 hours. Lectin-conjugate analgesia is similar in intensity to that of a 10 $\mu$ g/mouse supramaximal (20 times the mouse EC50) of morphine in this test but is of much longer duration; morphine achieves a maximal effect at 1 hour and then 10      declines over a period of 5 hours.

#### Example 7.

##### *In vivo* analgesic effects of a glucosyl-reactive lectin from *Triticum vulgaris*.

15

###### *Materials*

16        *Triticum vulgaris* wheat germ agglutinin lectin (WGA) was obtained from Sigma Ltd.

20        *Method*

Intrathecal administration of *Triticum vulgaris* lectin WGA was as described for Examples 5 and 6.

25        The data in Figure 4 shows that by 24-30 hours post application the hot-plate paw withdrawal time in WGA treated mice is much greater than that of PBS treated control groups. By 48 hours post application the analgesic effect from the single dose has dissipated.

#### Example 8.

30

*In vivo* analgesic effects of a galactosyl-reactive lectin IB<sub>4</sub> from *Bandeiraea simplicifolia*.

- 26 -

*Materials*

*Bandeiraea simplicifolia* lectin IB<sub>4</sub> was obtained from Sigma Ltd.

*Method*

- 5 Intrathecal administration of *Bandeiraea simplicifolia* lectin IB<sub>4</sub> was as described for Examples 5 and 6.

The data in Figure 5 shows the analgesic effect of a single intrathecal dose of lectin IB<sub>4</sub> reagent in a mouse hot plate model over a 10 hour period. A 10 significant increase in withdrawal latency is observed at 1 hour post application with an apparent maximal activity at 4 hours. Analgesia was still clearly discernible over control-group animals at 10 hours post application.

**Example 9.**

- 15 The production of a conjugate between *Triticum vulgaris* lectin and a companion protein.

*Materials*

- 20 Lectin from *Triticum vulgaris* (WGA) was obtained from Sigma Ltd.  
LH<sub>N</sub>/A was prepared essentially by the method of Shone C.C., Hambleton, P., and Melling, J. 1987, *Eur. J. Biochem.* 167, 175-180.  
SPDP was from Pierce Chemical Co.  
PD-10 desalting columns were from Pharmacia.

- 25 Dimethylsulphoxide (DMSO) was kept anhydrous by storage over a molecular sieve.  
Denaturing sodium dodecylsulphate polyacrylamide gel electrophoresis (SDS-PAGE) and non-denaturing polyacrylamide gel electrophoresis was performed  
30 using gels and reagents from Novex.

Additional reagents were obtained from Sigma Ltd.

- 27 -

*Method*

The lyophilised WGA lectin was rehydrated in phosphate buffered saline (PBS) to a final concentration of 10 mg/ml. Aliquots of this solution were stored at -20°C until use.

5

The WGA was reacted with an equal concentration of SPDP by the addition of a 10mM stock solution of SPDP in DMSO with mixing. After one hour at room temperature the reaction was terminated by desalting into PBS over a PD-10 column.

10

The thiopyridone leaving group was removed from the product to release a free -SH group by reduction with dithiothreitol (DTT; 5mM; 30 min). The thiopyridone and DTT were removed by once again desalting into PBS over a PD-10 column.

15

The companion protein, LH<sub>N</sub>/A, was desalted into PBSE (PBS containing 1mM EDTA). The resulting solution (0.5-1.0 mg/ml) was reacted with a four-fold molar excess of SPDP by addition of a 10mM stock solution of SPDP in DMSO. After 3 h at room temperature the reaction was terminated by 20 desalting over a PD-10 column into PBSE.

25

A portion of the derivatized LH<sub>N</sub>/A was removed from the solution and reduced with DTT (5mM, 30 min). This sample was analysed spectrophotometrically at 280nm and 343nm to determine the degree of derivatisation. The degree of derivatisation achieved was 3.53 ± 0.59 mol/mol.

The bulk of the derivatized LH<sub>N</sub>/A and the derivatized WGA were mixed in proportions such that the ExL was in greater than three-fold molar excess. The conjugation reaction was allowed to proceed for >16 h at 4°C.

30

The product mixture was centrifuged to clear any precipitate that had developed. The supernatant was concentrated by centrifugation through

- 28 -

concentrators (with 10000 molecular weight exclusion limit) before application to a Superose 12 column on an FPLC chromatography system (Pharmacia). The column was eluted with PBS and the elution profile followed at 280 nm.

5

Fractions were analysed by SDS-PAGE on 4-20% polyacrylamide gradient gels, followed by staining with Coomassie Blue (Figure 6). The major conjugate products have an apparent molecular mass of between 106-150kDa, these are separated from the bulk of the remaining unconjugated LH<sub>N</sub>/A and more completely from the unconjugated WGA.

10 Fractions containing conjugate were pooled prior to addition to PBS-washed N-acetylglucosamine-agarose. Lectin-containing proteins (ie. WGA-LH<sub>N</sub>/A conjugate) remained bound to the agarose during washing with PBS to remove contaminants (predominantly unconjugated LH<sub>N</sub>/A). WGA-LH<sub>N</sub>/A conjugate was eluted from the column by the addition of 0.3M N-acetylglucosamine (in PBS) and the elution profile followed at 280 nm.

15 The fractions containing conjugate were pooled, dialysed against PBS, and stored at 4°C until use.

20 On the gel there are bands due to lectin alone in fractions containing the conjugate, this material is probably due to the non-covalent homo-dimeric nature of the WGA; where only one monomer of WGA is covalently attached to the LH<sub>N</sub>/A the other is dissociated from the complex by the SDS in the electrophoretic procedure giving rise to these bands.

#### Example 10.

30 The production of a conjugate between *Erythrina corallodendron* lectin and a companion protein.

- 29 -

*Materials*

*Erythrina corallodendron* lectin was obtained from Sigma.

*Method*

- 5 The methodology for production of *Erythrina corallodendron* lectin conjugated to a companion protein is similar to that described in Example 9 for the production of WGA-LH<sub>N</sub>/A. See Figure 7 for SDS-PAGE analysis of conjugated protein.

10 **Example 11.**

**The production of a conjugate between *Bandeiraea simplicifolia* lectin and a companion protein.**

15 *Materials*

*Bandeiraea simplicifolia* lectin was obtained from Sigma.

*Method*

- 20 The methodology for production of *Bandeiraea simplicifolia* lectin conjugated to a companion protein is similar to that described in Example 9 for the production of WGA-LH<sub>N</sub>/A. See Figure 8 for SDS-PAGE analysis of conjugated protein.

**Example 12.**

25

**Preparation of oligomeric *Erythrina cristagalli* lectin.**

*Materials*

*Erythrina cristagalli* lectin was obtained from Sigma.

30

SPDP & SMPB were obtained from Pierce.

- 30 -

*Method*

The lyophilised lectin was rehydrated in phosphate buffered saline (PBS) to a final concentration of 2 mg/ml.

- 5 An aliquot of ECL was reacted with a 1.5 times molar excess of SPDP by the addition of a 10mM stock solution of SPDP in DMSO. After rotating for 90 minutes at room temperature, the reaction was terminated by desalting into PBS over a PD-10 column.
- 10 The thiopyridone leaving group was removed from the product to release a free -SH group by reduction with dithiothreitol (DTT; 5mM; 30 min). The thiopyridone and DTT were removed by once again desalting into PBS over a PD-10 column.
- 15 A second aliquot of ECL was reacted with a 2.5 times molar excess of SMPB (a non-reducible linker) by the addition of a 10mM stock solution of SMPB in DMSO. After rotating for 90 minutes at room temperature, the reaction was terminated by desalting into PBS over a PD-10 column.
- 20 The derivatised ECL samples were mixed together and the conjugation reaction was allowed to proceed by rotation at 4°C for >16 h.
- Aliquots of the derivatised lectins and the product mixture were analysed by SDS-PAGE on 4-20% polyacrylamide gradient gels, followed by staining with Coomassie Blue (see Figure 9).

**Example 13.**

**Preparation of recombinant *Erythrina cristagalli* lectin.**

30

*Materials*

Viable *Erythrina cristagalli* seeds were obtained from a local horticultural

- 31 -

distributor.

*Method*

5 A number of methods for obtaining the coding sequence for *Erythrina cristagalli* lectin (ECL) were employed. In the first instance, methodology similar to that described by Arango *et al* for *Erythrina corallodendron* [Arango, R., Rozenblatt, S., & Sharon, N. (1990), FEBS Lett. 264, 109-111] was used to isolate the coding sequence from messenger RNA.

10 Alternatively, the coding sequence for *Erythrina cristagalli* was obtained by specific amplification from genomic DNA. Briefly, genomic DNA was extracted from *Erythrina cristagalli* using commercially sourced DNA extraction kits. The sequence of the N-terminal amino acids of ECL was determined in order to facilitate primer design. Using degenerate primers designed to have 15 homology with the N-terminus of ECL and the published sequence of *Erythrina corallodendron*, amplification of coding region was facilitated.

20 Specific amplification product was isolated, cloned into a suitable vector and sequenced. Sequence data confirmed the presence of codons suitable for the expression of polypeptide that had homology to the lectin isolated from *Erythrina corallodendron*.

25 ECL coding region was cloned into a suitable expression vector and expression of recombinant ECL induced. Recombinant ECL was observed by Western blotting using antisera raised against native ECL.

**Example 14.**

***In vitro* modulation of C-fibre activity by *Erythrina cristagalli* lectin.**

30

**Materials**

Substance P EIA kit was obtained from Cayman Chemical Company (690

- 32 -

KMS Place, Ann Harbor, MI 48108, USA).

*Method*

5 Embryonic DRG were prepared according to Welch *et al* [Welch MJ, Foster KA. (1999) Embryonic rat spinal sensory ganglia. In: The Neuron in Tissue Culture (Haynes LW, ed), John Wiley and Sons. *IBRO Handbook Series: Methods in the Neurosciences* 18 389-392].

10 Material was applied between seven and fourteen days post initiation of culture and incubated for 3 days prior to assay. After washing with HBSS-D the substance P release capability of the cells was determined by the following method. Wells were washed twice with low potassium buffer (5mM KCl, 144mM NaCl, 1mM MgCl<sub>2</sub>, 0.4mM glucose, 10mM HEPES (pH 7.4), 2mM CaCl<sub>2</sub>).

15 Basal samples were then obtained by incubating each well for 5 minutes with 1ml low potassium buffer. Following removal of basal samples cells were stimulated by incubating with 1ml high potassium buffer (40-120mM KCl isotonically balanced with NaCl) for five minutes.

20 Substance P immunoreactivity was measured using the Substance P Enzyme Immunoassay Kit manufactured by Cayman Chemical Company (690 KMS Place, Ann Harbor, MI 48108, USA) according to manufacturers' instructions and is expressed in pg/ml relative to a standard substance P curve run in parallel.

30 *Erythrina cristagalli* lectin was demonstrated to modulate the release of substance P in a dose-dependent manner (see Figure 10). At low doses, release of substance P is slightly enhanced above control release, whereas at high concentrations release of substance P is clearly inhibited. This indicates that *Erythrina cristagalli* lectin is able to modulate the activity of C-fibres by preventing release of a key neurotransmitter.

- 33 -

**Example 15.**

***In vitro modulation of C-fibre activity by *Erythrina cristagalli* lectin-protein conjugates***

5

***Materials & Method***

The preparation of dorsal root ganglia (eDRG) and assay of substance P release were as described previously.

10 A lectin-protein conjugate of the type described in Example 17 was applied to eDRG and substance P release assessed. Figure 11 is representative of such an experiment and demonstrates that *Erythrina cristagalli* lectin conjugated to another protein is capable of modulating release of substance P from an *in vitro* model of C-fibres.

15

**Example 16.**

***In vivo modulation of C-fibre activity by *Erythrina cristagalli* lectin.***

20 ***Method***

Electrophysiological studies of C-fibre activity were conducted in anaesthetized Sprague-Dawley rats essentially as described by Diaz, A. and Dickenson, A.H. 1997 *Pain.* **69**, 93-100.

25 Briefly, anaesthesia was induced with 2-3% halothane in 66% N<sub>2</sub>O-33% O<sub>2</sub> and a tracheal cannula was inserted. Rats were placed in a stereotaxic frame and a laminectomy performed to expose segments L4-L5 of the spinal cord. Clamps caudal and rostral to exposed section held the cord rigid and the animals spontaneously breathed while maintained in a state of areflexia with  
30 1.5-1.8% halothane.

Extracellular recordings of convergent dorsal horn neurons were made with

- 34 -

polymer coated tungsten electrodes which were lowered into the spinal cord by a SCAT (Digitimer) microdrive to a mean depth of 700 $\mu$ m, corresponding to the main zone of output cells from the cord to the brain.

5 Data were captured and then analysed by Spike 2 software. Selected neurons had a clear short latency (0-20ms) A $\beta$ -fibre evoked response followed by A $\delta$ -fibre response and then C-fibre evoked response (90-300ms) after transcutaneous electrical stimulation (2ms wide pulses at a frequency of 0.5Hz) of the centre of the receptive field. Trains of sixteen stimuli allowed  
10 construction of post stimulus histograms. Any neuronal responses occurring 300-800ms post-stimulus were taken as the post-discharge/after-discharge of hyperexcitable neurons.

230 $\mu$ g lectin from *Erythrina cristagalli* was applied in 50 $\mu$ l and C-fibre activity  
15 observed. Figure 12 is illustrative of data obtained from such an approach and demonstrates the downward trend of C-fibre response, compared to controls, over the time of the experiment.

**Example 17.**

20

***In vivo* analgesic effects of *Erythrina cristagalli*-LH<sub>N</sub>/A(-) conjugates**

**Materials**

Using site-directed mutagenesis, a mutant of LH<sub>N</sub>/A (LH<sub>N</sub>/A(-)) was prepared  
25 that possessed a tyrosine residue at position 227 in place of the native histidine. This mutant is known in the art to result in a protein that is defective in its endopeptidase activity [Zhou, L., de Pavia, A., Liu, D., Aoki, R. & Dolly, J. O., 1995, Biochemistry, 34, 15175-].

30 LH<sub>N</sub>/A(-) was conjugated to a lectin from *Erythrina cristagalli* according to the method described in Example 11.

- 35 -

*Methods*

Intrathecal administration of *Erythrina cristagalli*-LH<sub>N</sub>A(-) conjugate was as described in Examples 5, 6 and 19.

5      **Example 18.**

*In vivo modulation of antidromic C-fibre activity by Erythrina cristagalli lectin.*

*Materials & Method*

10     The effect on antidromic C-fibre activity in response to application of *Erythrina cristagalli* was assessed *in vivo* following similar methodology to that reported by Pinter *et al* [Pinter, E., Brown, B., Hoult, J. R. S. & Brain, S. D. (1999) European Journal of Pharmacology, **369**, 91-98], Lambeck & Holzer [Lembeck, F. & Holzer, P. (1979) Naunyn-Schmiedeberg's Arch. Pharmacol., **310**, 175-183] and Garret *et al* [Garret, C., Carruette, A., Fardin, V., Moussaoui, S., Peyronel, J-F., Blanchard, J-C and Laduron, P. M. (1991) Proc. Natl. Acad. Sci., **88**, 10208-10212].

15

20     *Erythrina cristagalli* was demonstrated to reduce extravasation induced by antidromic C-fibre activity (see Fig. 13).

The neurogenic inflammatory response occurs as a result of neuropeptide release from the endings of stimulated primary afferent neurones. The major neuropeptides involved are considered to be substance P, which acts to increase microvascular permeability, so allowing the exudation of plasma proteins from the blood vessels into the tissues, and CGRP, which is a potent vasodilator, and potentiates the oedema response to substance P. These combined phenomena result in inflammatory oedema formation. Furthermore, neurogenic inflammation is thought to be a component of several disorders and diseases, ranging from sunburn and psoriasis in the skin, to migraine, asthma, and rheumatoid arthritis. This study investigated the ability of *Erythrina cristagalli* to modulate neurogenic inflammation induced by electrical

25

30

- 36 -

stimulation.

All experiments were carried out in accordance with the Animals (Scientific Procedures) Act 1986.

5

Neurogenic oedema formation in the rat hind paw *Erythrina cristagalli* was administered 4hr before the start of oedema measurements. Anaesthesia was induced and maintained by isoflurane. *Erythrina cristagalli* (1mg in 100 FI Tyrode's solution) was injected i.d into the innervated paw skin in two rats  
10 and Tyrode (vehicle control) injected similarly into two separate rats.

The rats were allowed to recover then left for 4hr before oedema measurements were carried out. Rats were anaesthetized for the terminal protocol by intraperitoneal injection of sodium pentobarbitone (Sagatal 60 mg  
15 kg<sup>-1</sup>). The tail vein was cannulated to allow the maintenance of anaesthesia with sodium pentobarbiton (15 mg ml<sup>-1</sup> i.v. as required). The ipsilateral hind limb was shaved and the saphenous nerve dissected clear of surrounding tissue. The nerves were then ligated centrally and immersed in mineral oil for the duration of the experiment. Rats were placed on an automatic heating pad  
20 to maintain the body temperature at 36-38°C.

The animals were left for about 20 min to allow a stabilisation period after dissection. The animals then received <sup>125</sup>I-bovine serum albumin (180kBq) and Evans Blue dye (0.2-0.5 ml of 2.5% w/v in saline) i.v. via the tail vein in order  
25 to visualize and quantify plasma extravasation in paw skin. The saphenous nerve was then carefully, without pulling, lifted onto a platinum electrode. The nerve was then stimulated (10 V, 1 ms, 2 Hz, 5 min) and plasma was allowed to accumulate for 0-30 min. At the end of the accumulation period, a blood sample was taken by cardiac puncture and centrifuged at 6000 g for  
30 4 min to obtain a plasma sample.

The animal was killed by anaesthetic overdose and cervical dislocation and

- 37 -

the skin of the innervated areas of both hind paws was removed and weighed. The gamma emissions from plasma and skin were measured in a multi-channel counter (Wallac, UK) and microvascular extravasation was calculated by comparison to a known volume of blood plasma. The plasma extravasated was calculated and expressed as the volume of plasma per 100 mg tissue for the stimulated and control untreated leg.

The results are shown in Fig. 13. Oedema formation induced via this protocol in previous experiments is normally observed as approximately 30 µl plasma /100mg tissue. It can be observed that the rat treated with vehicle produced the expected response. Both paws treated with *Erythrina cristagalli*, produced what may be described as a trend towards an inhibitory effect.

Thus *Erythrina cristagalli* modified neurogenic inflammation induced following electrically-mediated neuropeptide release.

#### **Example 19.**

##### ***In vivo modulation of C-fibre activity by Erythrina cristagalli lectin.***

20

##### *Animals*

Adult outbred mice (MF1) of either sex, weight range 20 to 30g have been used for these studies.

25 All animals were acclimatised by maintaining them in the room in which the tests are to be carried out for a minimum of 4 days.

##### *Materials & Method*

Test and control substances were administered by the intrathecal route using 30 the following procedure. Mice are anaesthetized by induction with 4% fluothane carried in a 50:50 mixture of oxygen and nitrous oxide with a flow rate of 400-500 cc per minute.

- 38 -

Once anaesthesia is induced the percentage is reduced to 1.5 to 2% for maintenance. The pelvis of the mouse is located, the fur is clipped around the appropriate area and a small incision (about 5mm) is made in the skin above the spinal column.

5

Test material is injected into the intrathecal space using a 30 gauge disposable needle attached to a 50 $\mu$ l Hamilton syringe with luer fitting. The site of injection was normally chosen to be between lumbar vertebrae 1 and 3. Holding the syringe at an angle of about 20° above the vertebral column the needle is inserted into the tissue to one side of the vertebrae so that it slips into the groove between the spinous and transverse processes. The needle is then moved carefully forward to the intervertebral space whilst decreasing the angle of the syringe to about 10°.

10

Once inserted into the appropriate spot a characteristic flick of the tail is often, but not invariably, observed. 5 $\mu$ l of test material is then injected into the intrathecal space and the needle withdrawn. The skin incision is then closed with a single wound clip and the animal placed in a box to allow recovery.

15

Mice have been observed to recover rapidly from this procedure and become fully mobile within two minutes.

20

Pre-injection data was acquired from all animals on the day before test substances are introduced. This pre-test data allows screening of animals exhibiting extreme responses to the various stimuli and allocation to groups such that the mean group latency was equivalent. Response to thermal stimuli (hot plate) was determined 20 hours post injection of test and control substances.

25

#### *Hot Plate*

The equipment is switched on to equilibrate for 15 minutes before tests

- 39 -

commence. The temperature is normally set at 55°C. Individual animals are placed on the surface of the hotplate and observed closely and the time noted when one hind paw is deliberately withdrawn from the surface.

- 5 At this point the animal is immediately removed from the apparatus. In order to prevent tissue damage due to profound analgesia a maximum duration of 30 seconds is allowed for this test.

10 Fig. 14 illustrates data obtained following application of a range of concentrations of *Erythrina cristagalli* lectin to the spinal cord. Response to thermal stimuli is modified in a dose-dependent manner, indicative of C-fibre modulation.

- 40 -

**CLAIMS**

1. Use of a lectin in the manufacture of a medicament for modulation of C-fibre neurone activity.  
5
2. Use according to Claim 1 of a lectin specific for galactosyl residues.
3. Use according to Claim 1 of a lectin specific for glucosyl residues.
- 10 4. Use of a nucleic acid sequence encoding the lectin defined in any of Claims 1-3 in the manufacture of medicament for modulation of C-fibre neurone activity.
- 15 5. A pharmaceutical composition comprising a first lectin, and a pharmaceutically acceptable carrier and/or diluent, wherein the composition is substantially free of Clostridial neurotoxin enzyme activity.
6. A composition according to Claim 5 wherein the first lectin is specific for galactosyl residues.  
20
7. A composition according to Claim 5 wherein the first lectin is specific for glucosyl residues.
- 25 8. A composition according to any of Claims 5-7 comprising a peptide or protein; or a pharmaceutical composition comprising a first lectin, a peptide or protein substantially free of Clostridial neurotoxin enzyme activity, and a pharmaceutically acceptable carrier and/or diluent.
9. A composition according to Claim 8 wherein the peptide or protein is a second lectin and the first and second lectins are different.  
30
10. A composition according to Claim 9 wherein the first lectin is specific

- 41 -

for galactosyl residues and the second lectin is specific for glycosyl residues.

11. A composition according to Claim 8 wherein the peptide or protein is  
an endopeptidase or a Clostridial neurotoxin substantially free of enzyme  
5 activity.

12. A composition according to any of Claims 5-11, wherein the first lectin  
and/or the second lectin if present is a lectin derivative, said derivative having  
been modified to remove a carbohydrate group whilst maintaining the ability  
10 of the derivative to bind C-fibres.

13. A composition comprising one or more nucleic acid sequence encoding  
the lectin/s recited in Claims 5-10, or one or more nucleic acid sequence  
encoding the lectin and peptide/protein recited in Claim 11.

15 14. A conjugate comprising a first lectin coupled to a peptide or protein,  
wherein said peptide or protein is substantially free of Clostridial neurotoxin  
enzyme activity and optionally has a C-fibre modulation activity.

20 15. A conjugate according to Claim 14 wherein the peptide or protein is a  
second lectin.

16. A conjugate according to Claim 14 or 15 wherein the first lectin is  
specific for galactosyl residues.

25 17. A conjugate according to Claim 14 or 15 wherein the first lectin is  
specific for glucosyl residues.

30 18. A conjugate according to Claim 15 wherein the first and second lectins  
are different.

19. A conjugate according to Claim 18 wherein the first lectin is specific for

- 42 -

galactosyl residues and the second lectin is specific for glucosyl residues.

20. A conjugate according to Claim 14, wherein the peptide or protein is an endopeptidase, or a Clostridial neurotoxin substantially free of enzyme activity.
- 5
21. A conjugate according to any of Claims 14-20 wherein the first lectin and/or the second lectin if present is a lectin derivative, said derivative having been modified to remove a carbohydrate group whilst maintaining the ability of the derivative to bind C-fibres.
- 10
22. A nucleic acid sequence encoding the conjugate of any of Claims 14-20.
- 15 23. Use of a composition according to any of Claims 5-13, or use of a conjugate according to any of Claims 14-21, or use of a nucleic acid sequence according to Claim 22, in the manufacture of a medicament for modulation of C-fibre activity.
- 20 24. Use according to any of Claims 1-4 or 23 for treatment of a disease or condition selected from pain, psoriasis, inflammation and mucus hypersecretion.
- 25 25. Use of a composition according to any of Claims 1-4 or 23 for inhibition of C-fibre activity.
26. Use of a composition according to any of Claims 1-4 or 23 for stimulation of C-fibre activity.
- 30 27. A method of modulating C-fibre activity comprising administering an effective amount of a lectin, or a composition according to any of Claims 5-13, or a conjugate according to any of Claims 14-21, or a nucleic acid

- 43 -

sequence according to Claim 22, to a patient.

28. A method according to Claim 27 for inhibiting C-fibre activity.

5 29. A method according to Claim 27 for stimulating C-fibre activity.

30. A method according to any of Claims 27-29 for treating a disease or condition selected from pain, psoriasis, inflammation and mucus hypersecretion.

10

31. A method of preparing a conjugate according to any of Claims 14-21, comprising coupling together, optionally via a linker, the first lectin and the peptide or protein.

15

32. A method of preparing a conjugate according to any of Claims 14-21, comprising expressing in a host a nucleic acid sequence according to Claim 22, optionally including a linker nucleic acid sequence located within the nucleic acid sequence of Claim 22 to provide a linker molecule between the first lectin and the peptide or protein of the conjugate.

20

1/13




Figure 1.

2/13

Lectins and Lectin Conjugates are Analgesic in a  
Mouse Hot-plate Model





Figure 2

3/13



**Figure 3**

4/13




Figure 4.





Figure 5.

5/13



**Figure 6.**

6/13




Figure 7.

7/13




Figure 8.

8/13




Figure 9.

9/13




Figure 10.

10/13




Figure 11.

11/13




Figure 12.

12/13

Rat	Pretreatment (-4h)	Paw	µl plasma /100mg tissue
1.	<i>Erythrina cristagalli</i> lectin	Stimulated	18.4
	None	Nonstimulated	4.7
2.	<i>Erythrina cristagalli</i> lectin	Stimulated	17.5
	Vehicle (Tyrode)	Stimulated	32.2
3.	None	Nonstimulated	4.3

Effect of *Erythrina cristagalli* lectin on neurogenic inflammation induced by stimulation of the rat saphenous nerve.

Figure 13

13/13




Figure 14

# INTERNATIONAL SEARCH REPORT

Int'l Application No  
PCT/00/01247

**A. CLASSIFICATION OF SUBJECT MATTER**

IPC 7 A61K38/16 A61K47/48 C07K19/00 C12N15/29 A61K48/00  
A61P25/00

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
IPC 7 A61K C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, MEDLINE

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	<p>WO 99 17806 A (DUGGAN MICHAEL JOHN ;MICROBIOLOGICAL RES AUTHORITY (GB); CHADDOCK) 15 April 1999 (1999-04-15) cited in the application</p> <p>abstract page 3, line 15 - line 24 page 4, line 17 - line 27 page 5, line 5 - line 10 page 7, line 22 -page 8, line 33 page 9, line 28 -page 10, line 9 page 10, line 20 - line 33 examples 1-3,9</p> <p>----- -/-</p>	<p>1,2,4-6, 8,9,13, 14,20, 22-24, 31,32</p>

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

\* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority, claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

1 August 2000

11/08/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Noë, V

## INTERNATIONAL SEARCH REPORT

Inte Application No  
PCT/GB 00/01247

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>WO 96 33273 A (DUGGAN MICHAEL JOHN ;FOSTER KEITH ALAN (GB); MICROBIOLOGICAL RES A)            24 October 1996 (1996-10-24)            abstract            page 1, line 18 -page 3, line 14            page 13, line 9 - line 17            ----</p>	1
A	<p>STREIT ET AL: "Histochemical localization of galactose-containing glycoconjugates in sensory neurons and their processes in the central and peripheral nervous system of the rat"            THE JOURNAL OF HISTOCHEMISTRY AND CYTOCHEMISTRY, US, NEW BRUNSWICK, NJ, vol. 33, no. 10, 1 July 1985 (1985-07-01), pages 1042-1052, XP002091075            cited in the application            abstract            page 1048, column 1, paragraph 2            page 1051, column 1, paragraph 4            ----</p>	1,24
A	<p>DATABASE BIOSIS 'Online!            BIOSCIENCES INFORMATION SERVICE,            PHILADELPHIA, PA, US; 1992            ARANGO R ET AL: "EXPRESSION OF ERYTHRINA-CORALLODENDRON LECTIN IN ESCHERICHIA-COLI"            Database accession no. PREV199294009879            XP002142529            cited in the application            abstract            &amp; EUROPEAN JOURNAL OF BIOCHEMISTRY, vol. 205, no. 2, 1992, pages 575-581,            ISSN: 0014-2956            -----</p>	13,22,23

## INTERNATIONAL SEARCH REPORT

International Application No. PCT/GB 00 01247

### FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.1

Although claims 27-32 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

-----

Continuation of Box I.1

Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

Inte[redacted] Application No  
PCT/[redacted] 00/01247

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 9917806	A 15-04-1999	AU 9357498 A		27-04-1999
		EP 0996468 A		03-05-2000
		ZA 9809138 A		27-05-1999
-----	-----	-----	-----	-----
WO 9633273	A 24-10-1996	AU 705924 B		03-06-1999
		AU 5339896 A		07-11-1996
		BG 101984 A		31-07-1998
		BR 9609870 A		06-04-1999
		CA 2218857 A		24-10-1996
		CZ 9703322 A		18-03-1998
		EP 0826051 A		04-03-1998
		HU 9802392 A		01-02-1999
		JP 11504006 T		06-04-1999
		NO 974845 A		18-12-1997
		PL 323006 A		02-03-1998
		SG 52602 A		28-09-1998
		SK 143597 A		09-09-1998
		US 5989545 A		23-11-1999
		ZA 9603129 A		22-10-1996

JC20 Rec'd PCT/PTO SEP 26 2001

9/937484

This PTO did not receive the following  
listed item(s)

NO POSTCARD

**ENT COOPERATION TREATY**  
**PCT**

**INTERNATIONAL SEARCH REPORT**

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference  GWS/MM/21034	<b>FOR FURTHER ACTION</b> see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.	
International application No.  PCT/GB 00/ 01247	International filing date (day/month/year)  31/03/2000	(Earliest) Priority Date (day/month/year)  31/03/1999
Applicant		

**MICROBIOLOGICAL RESEARCH AUTHORITY**

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 5 sheets

It is also accompanied by a copy of each prior art document cited in this report.

**1. Basis of the report**

- a. With regard to the **language**, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.
  - the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).
- b. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international search was carried out on the basis of the sequence listing:
  - contained in the international application in written form.
  - filed together with the international application in computer readable form.
  - furnished subsequently to this Authority in written form.
  - furnished subsequently to this Authority in computer readable form.
  - the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
  - the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

2.  **Certain claims were found unsearchable** (See Box I).

3.  **Unity of invention is lacking** (see Box II);

4. With regard to the **title**,

- the text is approved as submitted by the applicant.
- the text has been established by this Authority to read as follows:

**USE OF A LECTIN OR CONJUGATES FOR MODULATION OF C-FIBRE ACTIVITY**

5. With regard to the **abstract**,

- the text is approved as submitted by the applicant.
- the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. The figure of the **drawings** to be published with the abstract is Figure No.

- as suggested by the applicant.
- because the applicant failed to suggest a figure.
- because this figure better characterizes the invention.

None of the figures.

**FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210**

Continuation of Box I.1

Although claims 27-32 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

-----

Continuation of Box I.1

Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy

# INTERNATIONAL SEARCH REPORT

International Application No.

PCT/GB 00/01247

**A. CLASSIFICATION OF SUBJECT MATTER**

IPC 7 A61K38/16 A61K47/48 C07K19/00 C12N15/29 A61K48/00  
A61P25/00

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, MEDLINE

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	<p>WO 99 17806 A (DUGGAN MICHAEL JOHN ;MICROBIOLOGICAL RES AUTHORITY (GB); CHADDOCK) 15 April 1999 (1999-04-15) cited in the application</p> <p>abstract page 3, line 15 – line 24 page 4, line 17 – line 27 page 5, line 5 – line 10 page 7, line 22 –page 8, line 33 page 9, line 28 –page 10, line 9 page 10, line 20 – line 33 examples 1-3,9 ---</p> <p style="text-align: center;">-/-</p>	<p>1,2,4-6, 8,9,13, 14,20, 22-24, 31,32</p>

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

° Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

1 August 2000

Date of mailing of the international search report

11/08/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.  
Fax: (+31-70) 340-3016

Authorized officer

Noë, V

## INTERNATIONAL SEARCH REPORT

International Application No

P [REDACTED] GB 00/01247

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 96 33273 A (DUGGAN MICHAEL JOHN ;FOSTER KEITH ALAN (GB); MICROBIOLOGICAL RES A) 24 October 1996 (1996-10-24) abstract page 1, line 18 -page 3, line 14 page 13, line 9 - line 17 ---	1
A	STREIT ET AL: "Histochemical localization of galactose-containing glycoconjugates in sensory neurons and their processes in the central and peripheral nervous system of the rat" THE JOURNAL OF HISTOCHEMISTRY AND CYTOCHEMISTRY, US, NEW BRUNSWICK, NJ, vol. 33, no. 10, 1 July 1985 (1985-07-01), pages 1042-1052, XP002091075 cited in the application abstract page 1048, column 1, paragraph 2 page 1051, column 1, paragraph 4 ---	1,24
A	DATABASE BIOSIS 'Online! BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1992 ARANGO R ET AL: "EXPRESSION OF ERYTHRINA-CORALLODENDRON LECTIN IN ESCHERICHIA-COLI" Database accession no. PREV199294009879 XP002142529 cited in the application abstract & EUROPEAN JOURNAL OF BIOCHEMISTRY, vol. 205, no. 2, 1992, pages 575-581, ISSN: 0014-2956 -----	13,22,23

**INTERNATIONAL SEARCH REPORT**

Info on patent family members

International Application No

P [REDACTED] GB 00/01247

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 9917806	A 15-04-1999	AU 9357498	A	27-04-1999
		EP 0996468	A	03-05-2000
		ZA 9809138	A	27-05-1999
<hr/>				
WO 9633273	A 24-10-1996	AU 705924	B	03-06-1999
		AU 5339896	A	07-11-1996
		BG 101984	A	31-07-1998
		BR 9609870	A	06-04-1999
		CA 2218857	A	24-10-1996
		CZ 9703322	A	18-03-1998
		EP 0826051	A	04-03-1998
		HU 9802392	A	01-02-1999
		JP 11504006	T	06-04-1999
		NO 974845	A	18-12-1997
		PL 323006	A	02-03-1998
		SG 52602	A	28-09-1998
		SK 143597	A	09-09-1998
		US 5989545	A	23-11-1999
		ZA 9603129	A	22-10-1996
<hr/>				

PCT

W INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>7</sup> : <b>A61K 38/16, 47/48, C07K 19/00, C12N 15/29, A61K 48/00, A61P 25/00</b>		A1	(11) International Publication Number: <b>WO 00/57897</b> (43) International Publication Date: <b>5 October 2000 (05.10.00)</b>
(21) International Application Number: <b>PCT/GB00/01247</b>		(81) Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: <b>31 March 2000 (31.03.00)</b>		Published	
(30) Priority Data: <b>9907429.6 31 March 1999 (31.03.99) GB</b>		<i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(71) Applicant ( <i>for all designated States except US</i> ): MICROBIOLOGICAL RESEARCH AUTHORITY [GB/GB]; CAMR, Porton Down, Salisbury, Wiltshire SP4 0JG (GB).			
(72) Inventors; and			
(75) Inventors/Applicants ( <i>for US only</i> ): FOSTER, Keith, Alan [GB/GB]; Microbiological Research Authority CAMR, Porton Down, Salisbury, Wiltshire SP4 0JG (GB). CHADDOCK, John, Andrew [GB/GB]; Microbiological Research Authority CAMR, Porton Down, Salisbury, Wiltshire SP4 0JG (GB). QUINN, Conrad, Padraig [GB/GB]; Microbiological Research Authority CAMR, Porton Down, Salisbury, Wiltshire SP4 0JG (GB).			
(74) Agents: SCHLICH, George, William et al.; Mathys & Squire, 100 Gray's Inn Road, London WC1X 8AL (GB).			

(54) Title: USE OF A LECTIN OR CONJUGATES FOR MODULATION OF C-FIBRE ACTIVITY

(57) Abstract

The present invention relates to the treatment of pain and to compounds that modulate C-fibre activity. In particular, the present invention relates to the use of a lectin in the manufacture of a medicament for modulation of C-fibre neurone activity, and to lectin conjugates. The lectin conjugates comprise a lectin coupled to a peptide or protein, wherein the peptide or protein is substantially free of Clostridial neurotoxin enzyme activity. The present invention also concerns methods for manufacturing said conjugates. The compounds and compositions described have particular application in the treatment of diseases of which C-fibre activity is a component. Such diseases include pain, inflammation, psoriasis and other C-fibre related conditions.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

# INTERNATIONAL SEARCH REPORT

Int'l. Application No  
PCT/GB 00/01247

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K38/16 A61K47/48 C07K19/00 C12N15/29 A61K48/00  
A61P25/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, MEDLINE

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	<p>WO 99 17806 A (DUGGAN MICHAEL JOHN ;MICROBIOLOGICAL RES AUTHORITY (GB); CHADDOCK) 15 April 1999 (1999-04-15) cited in the application</p> <p>abstract page 3, line 15 - line 24 page 4, line 17 - line 27 page 5, line 5 - line 10 page 7, line 22 -page 8, line 33 page 9, line 28 -page 10, line 9 page 10, line 20 - line 33 examples 1-3,9</p> <p>---</p> <p>-/-</p>	<p>1,2,4-6, 8,9,13, 14,20, 22-24, 31,32</p>

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

### \* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- "&" document member of the same patent family

Date of the actual completion of the international search

1 August 2000

Date of mailing of the international search report

11/08/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.  
Fax (+31-70) 340-3016

Authorized officer

Noë, V

## INTERNATIONAL SEARCH REPORT

Inten Application No  
PCT/GB 00/01247

C(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 96 33273 A (DUGGAN MICHAEL JOHN ;FOSTER KEITH ALAN (GB); MICROBIOLOGICAL RES A) 24 October 1996 (1996-10-24) abstract page 1, line 18 -page 3, line 14 page 13, line 9 - line 17	1
A	STREIT ET AL: "Histochemical localization of galactose-containing glycoconjugates in sensory neurons and their processes in the central and peripheral nervous system of the rat" THE JOURNAL OF HISTOCHEMISTRY AND CYTOCHEMISTRY, US, NEW BRUNSWICK, NJ, vol. 33, no. 10, 1 July 1985 (1985-07-01), pages 1042-1052, XP002091075 cited in the application abstract page 1048, column 1, paragraph 2 page 1051, column 1, paragraph 4	1,24
A	DATABASE BIOSIS 'Online! BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1992 ARANGO R ET AL: "EXPRESSION OF ERYTHRINA-CORALLODENDRON LECTIN IN ESCHERICHIA-COLI" Database accession no. PREV199294009879 XP002142529 cited in the application abstract & EUROPEAN JOURNAL OF BIOCHEMISTRY, vol. 205, no. 2, 1992, pages 575-581, ISSN: 0014-2956	13,22,23

## INTERNATIONAL SEARCH REPORT

International Application No. PCT/GB 00 A1247

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.1

Although claims 27-32 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

---

Continuation of Box I.1

Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

Inte[redacted] Application No  
PCT/[redacted] 00/01247

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 9917806	A 15-04-1999	AU 9357498 A		27-04-1999
		EP 0996468 A		03-05-2000
		ZA 9809138 A		27-05-1999
WO 9633273	A 24-10-1996	AU 705924 B		03-06-1999
		AU 5339896 A		07-11-1996
		BG 101984 A		31-07-1998
		BR 9609870 A		06-04-1999
		CA 2218857 A		24-10-1996
		CZ 9703322 A		18-03-1998
		EP 0826051 A		04-03-1998
		HU 9802392 A		01-02-1999
		JP 11504006 T		06-04-1999
		NO 974845 A		18-12-1997
		PL 323006 A		02-03-1998
		SG 52602 A		28-09-1998
		SK 143597 A		09-09-1998
		US 5989545 A		23-11-1999
		ZA 9603129 A		22-10-1996